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“I almost wish I hadn't gone down that rabbit-hole — and 
yet — and yet — it's rather curious, you know, 
this sort of life! ” 
 
                                                    ---Alice 
                                                                     (From Alice’s Adventures in Wonderland by Lewis Carroll)
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ABSTRACT 
The innate immune system is the first line of defense against invading pathogens. 
Recognition of microbial ligands by the innate immune system relies on germ-line 
encoded, evolutionarily conserved receptors called pattern recognition receptors (PRRs). 
Toll-like receptors (TLRs) are one such family of PRRs and are involved in innate 
defenses to a variety of microbes. At the core of TLR signaling pathways are Toll 
interleukin-1 receptor (TIR) domain containing adapter proteins. Much of the specificity 
of TLR pathways arise from the differential use of these adapter proteins.  
The TLR signaling cascade that ensues upon ligand recognition is marked by 
finely orchestrated molecular interactions between the receptor and the TIR domain 
containing adapter proteins, as well as various downstream kinases and effector 
molecules. Conserving the structural integrity of the TLR components is thus essential 
for maintaining a robust host defense system. Sometimes, changes in a protein can be 
brought about by single nucleotide polymorphisms (SNPs). Studies carried out in this 
thesis focus on polymorphisms in MyD88 adapter-like (Mal) and myeloid differentiation 
protein 88 (MyD88), two TIR domain-containing adapter proteins, which incidentally are 
also highly polymorphic. 
Mal is a 235 amino acid protein that is involved in TLR2 and TLR4 signaling. 
The known polymorphisms in the coding region of Mal were screened with an aim to 
identify SNPs with altered signaling potential. A TIR domain polymorphism, D96N, was 
found to be completely defective in TLR2 and TLR4 signaling. Immortalized 
macrophage-like cell lines expressing D96N have impaired cytokine production as well 
xii 
as NF-κB activation. The reason for this loss-of-function phenotype is the inability of 
Mal D96N to bind the downstream adapter MyD88, an event necessary for signaling to 
occur. Genotyping studies reveal a very low frequency of this polymorphism in the 
population. 
Similar SNP analysis was carried out in myeloid differentiation protein 88 
(MyD88). MyD88 is a key signaling adapter in TLR signaling; critical for all TLR 
pathways except TLR3. In reporter assays, a death domain variant, S34Y, was found to 
be inactive. Importantly, in reconstituted macrophage-like cell lines derived from 
knockout mice, MyD88 S34Y was severely compromised in its ability to respond to all 
MyD88-dependent TLR ligands. S34Y mutant has a dramatically different localization 
pattern as compared to wild type MyD88. Unlike wild type MyD88, S34Y is unable to 
form distinct foci in the cells but is present diffused in the cytoplasm.  IRAK4, a 
downstream kinase, colocalizes with MyD88 in these aggregates or “Myddosomes”. 
S34Y MyD88, however, is unable to assemble into Myddosomes, thus demonstrating that 
proper cellular localization of MyD88 is a feature required for MyD88 function.    This  thesis  thus  describes  two  loss‐of‐function  polymorphisms  in  TLR adapter proteins Mal and MyD88. It sheds light not only on the structural aspects of signaling  by  these  two  proteins,  but  also  has  implications  for  the  development  of novel pharmaceutical agents. 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CHAPTER I 
 
 
 
 
 
 
 
 
                                          
 
 
INTRODUCTION 
2 
Introduction to Innate Immunity 
The immune system is a network of specialized cells, tissues and organs that 
protect an organism against invasion by various pathogenic microorganisms. Innate and 
adaptive immunity are two components of the immune system with distinct properties. 
Innate immune responses occur rapidly and are the first line of defense that the pathogen 
encounters. These responses are non-specific and lack immunologic memory. An 
important characteristic of innate immunity is the ability to distinguish “non-self” from 
“self” and this is achieved by the use of pattern recognition receptors. Adaptive immune 
responses on the other hand have much slower kinetics and are highly specific. They 
have the unique feature of immunologic memory that allows them to mount a stronger 
and faster response to a subsequent infection by the same microorganism.  
 While B and T lymphocytes are the key players in an adaptive immune response, 
the innate response employs a variety of cells of both myeloid and lymphoid lineage. 
These include mast cells, natural killer cells, eosinophils, basophils as well as the 
phagocytic cells like dendritic cells (DCs), macrophages and neutrophils. 
 
Mast cells: Mast cells are a type of innate immune cells that are closely associated with 
connective tissue and mucous membranes. They are best known for mediating allergic 
responses, but are also involved in wound healing and in protecting the internal surfaces 
of the body against pathogens (1, 2). They have large coarse granules in their cytoplasm 
that store a number of different chemical mediators like histamine, interleukins, heparin 
and various proteolytic enzymes (3). Upon stimulation, the contents of these granules are 
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released into the surrounding tissues, producing local responses characteristic of an 
inflammatory reaction. Histamine dilates blood vessels and helps in recruitment of 
macrophages and neutrophils (4). 
 
Neutrophils: Neutrophils are a type of granulocyte (along with basophils and 
eosinophils) and are also called polymorphonuclear cells because of the distinctive 
appearance of their nuclei. In comparison with macrophages, neutrophils are relatively 
short-lived and survive for only a few days. However, they are the most abundant of all 
phagocytes and are highly motile. Thus, during infection neutrophils are the first cells to 
reach the site and defend against invading pathogens. Similar to macrophages, 
neutrophils attack pathogens by activating a respiratory burst. The main products of the 
neutrophil respiratory burst are strong oxidizing agents including hydrogen peroxide, free 
oxygen radicals and hypochlorite.  
 
Dendritic cells (DCs): Dendritic cells are potent antigen presenting cells (APCs) and 
function to stimulate naïve T-cells (5). They thus act as a link between innate and 
adaptive immunity. DCs are present in a number of tissues, especially those that are in 
contact with the external environment like the skin  (where they are called Langerhans 
cells) and the inner lining of lungs, nose, stomach and intestines. Numerous projections 
or “dendrites” that extend from the main cell body, give the cells a unique appearance 
and are the basis for the term “dendritic cells”.  DCs are not a single population, but 
comprise a heterogeneous collection of cells derived from distinct hematopoietic lineages 
4 
(6). Broadly, DCs can be categorized into plasmacytoid dendritic cells (pDCs) and 
myeloid dendritic cells (mDCs, also known as classical dendritic cells). pDCs comprise 
only 0.2-0.8% of human blood cells and are so named because of their morphological 
similarity with plasma cells (7). They can produce type I IFN and were known as IFN 
producing cells (IPC) before their dendritic nature was revealed (7). Both pDCs and 
mDCs express pattern recognition receptors, especially TLRs. However, they both have a 
distinct expression profile in relation to the TLRs they express. mDCs express TLR1, 
TLR2, TLR3, TLR4 and TLR8, while pDCs express high levels of TLR 7 and TLR9. 
pDCs thus, predominantly respond to microbial nucleic acids, whereas mDCs can 
recognize a broader range of ligands. 
 
Natural killer cells (NK cells): NK cells are a type of cytotoxic lymphocyte that are a 
part of the innate immune system (8). They are generated from the same lymphoid 
precursors as the B and T cells. They are also known as large granular lymphocytes and 
play an important role in the rejection of tumors and host defense against virally infected 
cells (9). NK cells are cytotoxic. They have small granules in their cytoplasm containing 
proteins known as perforins and proteases called granzymes (10). Upon coming close to a 
cell slated for death, perforins form channels in the membrane of the cell, through which 
granzymes and other proteins can enter, thus inducing apoptosis (11). 
 
Macrophages: Macrophages are resident phagocytic cells that differentiate from 
circulating peripheral-blood mononuclear-cells (PBMCs) (12). PBMCs develop from 
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myeloid progenitor cells in the bone marrow, which are also the precursors to other cell 
types like dendritic cells. In response to macrophage colony-stimulating factor, cells of 
the monocyte lineage (which differentiate from myeloid progenitors) divide and 
differentiate into monoblasts and then pro-monocytes. They then become monocytes 
which are released from the bone marrow and enter the blood stream. Monocytes migrate 
from the blood into tissues to replenish tissue-resident macrophages (13). Macrophages in 
different tissues are markedly heterogeneous and reflect specialization of function in 
different microenvironments. In additon to lymphoid organs, macrophages are found in 
brain (microglial cells), liver (Kupffer cells), lung (alveolar macrophages), reproductive 
organs and the interstitium of organs like the heart and kidney, lamina propria of the gut 
etc. They are prodigious phagocytic cells and are involved in the clearing of cellular 
debris and cells that have undergone apoptosis. Trauma or stress induced necrosis also 
results in cellular debris that can be cleared by macrophages. They are equipped with a 
variety of receptors for phagocytosis like complement receptors and Fc receptors (14, 
15). Additionally, they are equipped with a broad range of pattern recognition receptors 
that make them one of the primary sensors of danger in the host (16). These receptors are 
involved in the recognition of different pathogen associated molecules, triggering various 
signaling pathways to mount an immune response. Upon encountering a pathogen, a 
macrophage engulfs the pathogen and forms an internal membrane bound compartment 
called the phagosome. The phagosome fuses with the lysosome to form a phagolysosome. 
Various metabolic enzymes, nitric oxide, oxygen radicals and other chemical mediators 
in the phagolysosome digest and kill the pathogen by a process known as “respiratory 
6 
burst”. In addition, macrophages release cytokines and chemokines that are involved in 
the inflammatory response and help recruit other cells like DCs.  
 Depending upon the type of cytokines they are exposed to, macrophages can be 
classified as either classically activated macrophages or alternative activated 
macrophages. The former category is used to describe effector macrophages produced 
during cell-mediated immune responses (17, 18). Exposure of macrophages to IFN-γ or 
TNF results in a population of cells that have high microbicidal activity and secrete high 
levels of pro-inflammatory cytokines and mediators (19). In the latter case, exposure to 
IL-4, IL-10 or IL-13, produces a macrophage population that can induce cellular 
proliferation and the production of polyamines and collagen, thereby contributing to 
wound healing (17, 20). 
  
Pattern recognition receptors 
In 1989, Charles Janeway Jr., proposed the pattern recognition theory, which laid 
the foundation for our current understanding of innate immunity (21). The innate immune 
system relies on germ-line encoded, evolutionarily conserved receptors called pattern 
recognition receptors (PRRs) to sense microbes (22). These receptors recognize 
conserved structures in microbes called pathogen associated molecular patterns (PAMPs). 
Since PAMPs are broadly expressed in pathogens and not in host cells, PRRs are able to 
differentiate between self and non-self. Depending on their location, these PRRs can be 
classified into transmembrane proteins, which include Toll-like receptors (TLRs) and C-
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type lectin receptors (CLRs) as well as cytosolic proteins such as Retinoic acid-inducible 
gene (RIG)-I-like-receptors (RLRs) and NOD-like receptors (NLRs).  
 
C-type lectin receptors (CLRs): C-type lectin receptors (CLRs) are a family of 
receptors that bind carbohydrates in a calcium dependent manner (23, 24). The sugar 
binding property of CLRs can be attributed to the presence of highly conserved 
carbohydrate recognition domains (CRDs) (24). CLRs include dectin-1, the dendritic 
cell-specific ICAM3-grabbing non-integrin (DC-SIGN), DC-SIGN related (DC-SIGNR), 
Mannose receptor (MR) and the circulating mannose binding lectin (MBL). They are 
expressed on most cell types, including macrophages and dendritic cells  (DCs) and are 
mostly involved in defense against fungi. Mannose receptor (MR) was one of the first 
fungal PRRs to be described. It recognizes the mannose moieties in the cell walls of 
bacteria, viruses and various species of fungi (25, 26). Dectin-1, an immunoreceptor 
tyrosine-based activation motif (ITAM)-containing CLR is expressed on phagocytes and 
is a specific receptor for β-glucans which are sugar polymers found in the cell walls of 
fungi, including the yeasts Saccharomyces cerevisiae and Candida albicans (27-29). 
Dectin-2 recognizes hyphal forms of fungi (30, 31). DC-SIGN has been implicated in the 
recognition of various viruses and other microbes. It is of particular importance because 
of its role in HIV recognition (32, 33). 
 
RIG-I-like receptors (RLRs): RLR family of cytoplasmic receptors consists of retinoic-
acid-inducible protein 1 (RIG-I), melanoma-differentiation-associated gene 5 (MDA-5) 
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and laboratory of genetics and physiology 2 (LGP2) (34, 35). RIG-I and MDA-5 
recognize genomic RNA from dsRNA viruses as well as the dsRNA generated as the 
replication intermediate in ssRNA viruses and lead to type 1 IFN production and pro-
inflammatory cytokines. Both RIG-I and MDA-5 have two caspase recruitment domains 
(CARDs) and a DEAD box helicase/ATPase domain (36). LGP2 lacks the CARD 
domain and was initially considered a negative regulator of RIG-I and MDA-5 pathways 
(37). Recently, however, it has been demonstrated that LGP2 acts upstream of RIG-I and 
MDA-5 and facilitates viral RNA recognition by these two proteins via its ATPase 
domain (38). 
 Despite a similar domain structure, RIG-I and MDA-5 detect distinctly different 
viral species. While RIG-I is implicated in the recognition of Paramyxoviruses 
[Newcastle disease virus (NDV), Sendai virus (SeV)], Orthomyxoviruses (Influenza), 
vesicular stomatitis virus (VSV), Japanese encephalitis virus (JEV) and Hepatitis C virus 
(HCV), MDA-5 is essential for recognition of picornaviruses such as encephalo-
myocarditis virus (EMCV) and the synthetic dsRNA analog poly (I:C) (39, 40). Dengue 
virus and West Nile virus are recognized by both RIG-I and MDA-5. Short dsRNA with a 
5’ triphosphate end is the preferred ligand for RIG-I, whereas MDA-5 detects long 
dsRNA (more than 2kb) (41-43). However, the signaling pathway downstream of both 
RIG-I and MDA-5 are similar. Upon recognition of dsRNA, they are recruited to the 
mitochondrial outer membrane via the adapter MAVS (also called IPS-1, CARDIF or 
VISA), ultimately leading to the activation of several transcription factors like IRF3, 
IRF7 and NF-κB (44). 
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NOD-like receptors (NLRs): NLRs are a family of cytosolic receptors containing more 
than 20 members (45). They are characterized by a tripartite domain structure comprising 
an N-terminal protein interaction domain, a central nucleotide binding oligomerization 
domain (NOD, also called NACHT domain) and a C-terminal region consisting of 
leucine-rich repeats (LRRs) (46). The N-terminal domain that mediates protein-protein 
interactions, also serves as the criteria for categorizing the NLR proteins (45). To date, at 
least 23 human and 34 mouse NLR genes have been identified (47). The function of most 
NLRs however remains as yet uncharacterized.  
NOD1 and NOD2 were the first NLRs to be implicated in sensing of PAMPs 
having one and two CARD domains respectively at their N-terminus. Both NOD1 and 
NOD2 recognize the structures of peptidoglycan, a component of the bacterial cell wall 
(48). NOD1 recognizes g-D-gultamyl-mesodiaminopimelic acid (iE-DAP), while NOD2 
binds muramyl dipeptide (MDP) (49, 50). They both induce NF-κB activation by 
engaging the adapter RIP2/RICK and lead to pro-inflammatory cytokine production. 
Certain NLRs have a pyrin domain or a baculovirus inhibitor of apoptosis protein 
repeat (BIR) domain and are involved in the release of IL-1 family of cytokines including 
IL-1β, IL-18 and IL-33 (51). These proteins are components of large complexes called 
the “inflammasomes”, which regulate the activity of caspase-1. Caspase-1 processes the 
pro-form of these cytokines into mature bio-active mediators. Three NLR proteins NLR 
family PYD-containing 1 (NLRP1), NLRP3 and NLR family CARD-containing 4 
(NLRC4) {also called ICE (caspase-1 converting enzyme) protease activating factor 
[IPAF]} have been identified to form inflammasomes (52).  Inflammasome complexes 
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involve one or more NLR proteins, caspase-1 and the adapter protein apoptosis-
associated speck-like protein containing a CARD (ASC) (51). 
 Of all the inflammasomes, NLRP3 is the best characterized. A wide range of 
stimuli have been reported to activate the NLRP3 inflammasome. These include 
crystalline substances like uric acid crystals, silica, asbestos, β-amyloid fibrils and 
cholesterol crystals as well as bacteria, fungi and viruses (53-60). NLRC4 inflammasome 
is activated by the flagellin protein of bacteria (61).  
 
Cytosolic DNA receptors: Although the recognition of CpG DNA motifs in the 
lysosomal compartment is attributed to TLR9, when dsDNA is released free into the 
cytoplasm, it promotes type I IFN responses through TLR9-independent pathways. These 
responses are chiefly mediated via the activation of TBK1 [TNFR-associated factor 
(TRAF) family member-associated nuclear factor κB (NF-κB) activator (TANK)-binding 
kinase-1], a kinase that phosphorylates and activates the transcription factor IRF3 (62).  
DNA-dependent activator of IFN-regulatory factors (DAI), also known as ZBP1 or  DLM‐1  was the first DNA sensor implicated in the recognition of dsDNA in the 
cytoplasm (63). However, DAI deficient mice are still capable of producing IFN in 
response to cytoplasmic DNA, suggesting that DAI may play a redundant role in sensing 
cytosolic DNA (64). Two studies have shown that poly (dA.dT) can be transcribed into 
dsRNA by RNA polymerase III, which can then be detected by the RIG-I pathway (65, 
66). However, DCs from RIG-I deficient mice have no defect in IFN production, 
signifying that cytosolic DNA detection can be cell type dependent (67). Type I IFN 
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production by both DAI and RIG-I converge on TBK1 and stimulator of IFN genes 
(STING), an endoplasmic reticulum (ER)-resident protein that functions as an adapter 
upstream of TBK1 (68, 69).  
Recently, a member of the PYHIN protein family (pyrin and HIN200 domain–
containing proteins), IFI16 and its closest mouse homolog p204 was reported to detect 
cytosolic viral DNA and induce type I IFN (70). Another report characterizes LRRFIP1 
as a protein that signals via β-catenin and detects nucleic acids leading to activation of 
IFN-β by a coactivator pathway (71). Another PYHIN protein, AIM2 is involved in 
recognition of cytosolic DNA (72). AIM2 binds dsDNA through its HIN domain, 
promoting the assembly of an inflammasome with the adapter protein ASC, leading to 
caspase-1 activation (73, 74). AIM2 however has no role in the induction of IFN α/β.  
  
Toll-like receptors (TLRs) 
TLRs are the most well characterized and studied pattern recognition receptors. 
They are named for their similarity to Toll, a receptor first discovered in the fruit fly 
Drosophila. Toll was originally known for its role in embryonic development and 
establishing dorsal-ventral polarity of the embryo (75-77). In 1996, Lemaitre et al. 
demonstrated that the adult flies with the mutation in Toll were more susceptible to 
fungal infection and that the activation of Toll resulted in the production of anti-fungal 
peptides (78). The Drosophila Toll has a structure homologous to the interleukin-1 
receptor (IL-1R) and it activates a transcription factor called Dorsal, which is a homolog 
of the mammalian NF-κB. Receptors and signaling pathways that are similar to the 
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Drosophila Toll have since been called Toll-like receptor (TLR) pathways. To date, 
thirteen TLRs have been identified in mice and ten in humans, each defined by its 
specificity for a particular PAMP. TLR1-TLR9 are conserved between humans and mice. 
TLR10 is non-functional in mice because of a retroviral insertion whereas TLR11, 
TLR12 and TLR13 have been lost from the human genomes. 
Location of TLRs and their specificities for ligands 
TLRs can be categorized into two subfamilies on the basis of their location in the 
cell. TLR1, TLR2, TLR4, TLR5 and TLR6 are expressed on the cell surface and respond 
mainly to bacterial surface associated PAMPs. TLR3, TLR7, TLR8 and TLR9 on the 
other hand, are expressed in the intracellular compartments like endosome, lysosome or 
endoplasmic reticulum (ER) and sense viral and bacterial nucleic acids (FIG I.1). The 
activation of these TLRs leads to type I IFN production in addition to pro-inflammatory 
cytokines. 
 A human homolog of Toll (hToll), now known as TLR4, was the first TLR to be 
discovered and was demonstrated to be the signal transducing component involved in 
responses to lipopolysaccharide (LPS) (79, 80). LPS is a component of the outer 
membrane of Gram-negative bacteria. C3H/HeJ mice are unable to mount an innate 
immune response against bacterial LPS. This defect was mapped to a point mutation 
(proline to histidine at residue 712) in the gene encoding for TLR4 (81, 82). In addition to 
being the receptor for LPS, TLR4 recognizes envelope proteins of some viruses, such as 
respiratory syncytial virus (RSV) and mouse mammary tumor virus (MMTV) (83-86). 
TLR4 is discussed in greater detail in later sections. 
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FIGURE I.1: Human Toll-like receptors and their ligands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE I.1: Human Toll-like receptors at their respective locations in the cell. The best 
known ligands for each TLR are indicated. 
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TLR2 recognizes a variety of PAMPs from a range of bacteria, fungi, viruses and 
mycoplasma. TLR2 forms a heterodimer with either TLR1 or TLR6, and does not signal 
effectively as a homodimer  (87). The resulting TLR2/TLR1 and TLR2/TLR6 
heterodimers recognize triacyl and diacyl lipoproteins respectively (88). Other ligands for 
TLR2 include peptidoglycan and lipoteichoic acid (45) from Gram-positive bacteria, 
porin from Neisseria, zymosan from fungi, Trypanosoma GPI-mucin and hemagglutinin 
protein from measles virus. TLR2 also collaborates with the CLR Dectin-1 to mount an 
inflammatory response against zymosan. 
TLR5 recognizes flagellin, a protein found in bacterial flagella (89). It is 
expressed mostly on the surface of monocytes and epithelial cells (90). It has been 
implicated in protection against flagellated bacteria in the gut as well as in the urinary 
tract (91).  Mouse TLR11 is related to TLR5 and is expressed mostly in the kidney and 
bladder. TLR11 deficient mice are highly susceptible to infection by uropathogenic E.coli 
(92). TLR11 also recognizes a profilin like molecule from Toxoplasma gondi that is 
implicated in parasite motility and invasion (93, 94). 
TLR3 recognizes polyinosinic-polycytidylic acid (poly I:C), a synthetic dsRNA 
analog (95). It is also involved in innate defenses against genomic RNA from dsRNA 
viruses, as well as dsRNA produced as a replication intermediate of ssRNA viruses such 
as RSV and West Nile virus (WNV) (96, 97). Mouse TLR7 and human TLR7/TLR8 
recognize ssRNA from RNA viruses as well as imidazoqinoline derivatives like 
imiquimod (Human and mouse TLR7) and resiquimod (R848) (human, mouse TLR7 & 
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human TLR8) (98-101). TLR7 also detects RNA from bacteria such as Group B 
Streptococcus in endolysosomes of dendritic cells (DCs) (102). 
 TLR9 is the receptor for bacterial as well as viral DNA (103). It recognizes 
unmethylated 2’ deoxyribo cytidine-phosphate-guanosine (CpG) DNA motifs, commonly 
present in the genomes of bacteria and viruses (104, 105). In vertebrates however, CpG 
motifs are present at a much lower frequency and the cytosine residues of the CpG motifs 
are heavily methylated, thus preventing immunostimulatory responses against host DNA 
(106, 107).  TLR9 has also been shown to recognize malarial parasite DNA that is bound 
to hemozoin, a crystalline metabolite of hemoglobin, produced by the malaria parasite 
(108). Hemozoin acts as a carrier for DNA and transports it to the endosome, where 
TLR9 is present. 
Structure of TLRs  
All TLRs are type I transmembrane proteins (the N-terminus is outside the 
membrane) composed of three domains. The ectodomain is characterized by leucine-rich 
repeats (LRRs) and is responsible for recognizing the ligand. There is also a 
transmembrane domain followed by a C-terminal Toll/IL-1R (TIR) domain that is 
homologous to that of IL-1R. The TIR domain is the functional domain that is required 
for recruiting the downstream effectors and initiating the signaling pathway. The LRR 
domain consists of 19-25 tandem copies of the LRR motif, each 20-30 amino acids in 
length and comprises a β strand and an α helix, connected by a loop (109). This forms a 
horseshoe shaped structure that is involved in ligand binding (110). 
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TIR domain: The crystal structures of the TIR domains of TLR2 and TLR1 have been 
resolved, providing insight into the molecular aspects of the TIR domain (111). Both the 
structures reveal a central five-stranded parallel β-sheet surrounded by five α-helices. β-
sheets and α-helices alternate with structured loops of varying length connecting them. 
The loop between the second β-sheet and the second α-helix is called the BB loop and is 
conserved in many TLRs. The BB loop is also the site for P681H mutation in TLR2, 
which has been shown to be homologous to the TLR4 P712H mutation, a single base 
change that ablates LPS signaling through TLR4 and renders C3H/HeJ mice resistant to 
endotoxin shock (81, 112). The conserved residues in the TIR domain are located mostly 
in the hydrophobic core of the structure. The start and end of the core TIR domain have a 
conserved (F/Y)DA and FW amino acid motif respectively with the alanine residue of the 
(F/Y)DA motif being the first amino acid. TIR domain may be considered as a cassette 
with the amino and carboxy terminals of the core domain located within 14 Å of each 
other. The loop regions of different TIR domains have large insertions or deletions. The 
size of the core TIR domain thus varies between 135 to 160 residues among the different 
proteins. 
Ligand binding and TLR activation mechanism: insights from TLR-ligand crystal 
structures 
Crystallographic structures of the extracellular domains of TLRs in complex with 
their ligands have been resolved for four different TLR-ligand complexes. Three of them 
employ agonistic ligands, while the fourth is a complex of the extracellular domain with 
an antagonist. These structures not only provide insights into the mode of recognition of 
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microbial patterns by TLRs; they suggest an activation mechanism that may be employed 
by TLR family members.  
 The crystal structure of the extracellular domains of TLR2 and TLR1 has been 
determined in association with a synthetic triacylated lipopeptide, Pam3CSK4 (113). The 
extracellular domains of TLRs comprise of a variable number of LRR motifs forming a 
typical horseshoe shaped structure. Both TLR2 and TLR1 extracellular domains exist as 
monomers in solution. However, addition of the agonist, Pam3CSK4 leads to the 
formation of a heterodimer with the lipid chains of the ligand bridging the TLRs. Two 
lipid chains of the lipopeptide are inserted into a pocket in TLR2, whereas the third chain 
inserts into a hydrophobic channel in TLR1. Additional hydrophobic interactions 
between TLR1 and TLR2 help to stabilize the heterodimer.  
 The crystal structure of two TLR3 ectodomains with the ligand, dsRNA, reveals 
that each RNA molecule binds to the ectodomain at two sites located at the opposite ends 
of the TLR3 horseshoe (95). The sugar-phosphate backbone of dsRNA interacts with the 
positively charged residues of TLR3, explaining why TLR3 lacks specificity for any 
particular sequence. In the TLR3 ectomdomain:dsRNA complex, the C-termini of the 
two monomeric TLR3 ectodomains are brought into close proximity, mediating protein-
protein interactions. Thus, ligand-protein interaction is the main driving force behind 
TLR3 dimerization (95, 114). 
 TLR4 in association with MD-2 is responsible for the physiological response to 
LPS. Crystal structures of TLR4:MD-2 heterodimer in complex with LPS (agonist) as 
well as eritoran (antagonist) have been resolved (115, 116). The TLR4:MD-2:LPS 
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structure is a “m”-shaped multimer comprised of two TLR4:MD-2:LPS complexes or 
“units” (116). On the other hand, TLR4:MD-2:eritoran complex crystallized as a single 
unit (115). Both LPS as well as Eritoran bind to MD-2.  The differential ability of LPS 
and Eritoran to dimerize two single units of TLR4:MD-2 is due to their different 
chemical structure. The lipid A moiety of LPS has two phosphorylated glucosamines and 
6 acylated lipid chains. Eritoran however has only 4 lipid chains. LPS binds in a large 
hydrophobic pocket in MD-2. The two extra lipid chains in LPS displace the glucosamine 
backbone upwards, repositioning the phosphates which are now able to interact with 
positively charged residues in the second TLR4 molecule (of the second TLR4:MD-
2:LPS unit) (116). 
 The structures of all TLR-ligand complexes determined to date reveal an “m”-
shaped dimeric architecture. This suggests that dimerization of extracellular domains 
brings about TIR domain dimerization, thus initiating signaling (117). According to these 
structures, the C-termini of the extracellular domains converge to bring about close 
juxtaposition of the TIR domains, creating a scaffold for the intracellular adapter proteins 
(117). In the case of TLR9, it has been demonstrated that in a resting state, TLR9 exists 
as inactive dimers (118). However, binding to stimulatory DNA induces conformational 
changes that lead to close apposition of the TIR domains, enabling the recruitment of the 
downstream adapter MyD88. Thus, irrespective of whether the TLRs exist as preformed 
dimers or not, ligand binding induces changes in the conformation of the TIR domain, 
creating a scaffold for initiation of signaling. 
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Adapters in TLR signaling  
Binding of various PAMPs to TLRs leads to activation of distinct genes, 
depending on the particular TLR and the cell type involved. This specificity of signaling 
can be attributed mostly to the differential usage of TIR domain containing adapter 
proteins. There are five TIR domain containing adapters: myeloid differentiation protein 
88 (MyD88), MyD88 adapter-like (Mal) or TIR domain-containing adapter protein 
(TIRAP), TIR domain containing adapter inducing IFN-β (TRIF; also known as TICAM-
1), TRIF-related adapter molecule (TRAM) and Sterile-alpha and Armadillo motif-
containing protein (SARM) (FIG I.2). 
  
MyD88 (myeloid differentiation protein 88):  MyD88 was discovered in 1990 as a 
protein that was induced during terminal differentiation of M1D+ myeloid precursors in 
response to stimulation by IL-6. “88” refers to the gene number in the list of induced 
genes (119). Later, MyD88 was shown to have a role in IL-1R1 signaling as well as TLR 
signaling (120-122). In 1997, S. Akira’s group generated MyD88 deficient mice and they 
were found to be largely defective in their responses to TLR2, TLR4, TLR5, TLR7 and 
TLR9 signaling (123). Moreover, these mice are resistant to the toxic effects of LPS and 
are severely compromised in their ability to clear infections by various pathogens ranging 
from bacterial species like Staphylococcus aureus and Listeria monocytogenes to the 
protozoan parasite Leishmania major (124, 125).  Macrophages isolated from these mice 
have impaired cytokine production (like TNF-α and IL-6) in response to LPS. However, 
NF-κB and MAPK activation is not abrogated, though it occurs with delayed kinetics.  
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FIGURE I.2: TIR domain containing adapters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE I.2: A schematic depiction of the domain structure of the TIR domain 
containing adapters in TLR signaling. MyD88 has a death domain, an intermediary 
domain and a TIR domain. Mal/TIRAP has a phosphatidylinositol-4,5-bisphosphate 
(PIP2) binding domain at the N-terminus and a TIR domain at the C-terminus. TRIF has 
a RHIM domain and a TRAF6-binding domain (T6BM) in addition to a TIR domain. 
TRAM is myristoylated at its amino terminus. Although SARM has a TIR domain, it is 
not an adapter protein. It also has two sterile α-motif domains. 
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It was later discovered that MyD88-independent pathway mediated by the adapters TRIF 
and TRAM are responsible for this delayed response. 
 MyD88 is considered to be a universal adapter required for signaling of all TLRs 
(except TLR3) as well as IL-1R and IL-18R. TLR4 is unique as both a MyD88-
dependent and a MyD88-independent pathway are initiated upon recognizing LPS. 
MyD88 is a 296 amino acid protein that has a death domain at its N-terminus and a TIR 
domain at its C-terminus. The death domain (in conjugation with the intermediate region) 
of MyD88 is important for recruiting the downstream kinases IRAK-1 and IRAK-4, 
while the TIR domain is responsible for TIR-TIR interactions with TLRs as well as IL1R 
and IL-18R (126). In the case of TLR2 and TLR4 signaling however, the bridging 
adapter Mal is needed for signaling. MyD88 is mostly involved in NF-κB activation and 
pro-inflammatory cytokine production. However, it also leads to type I IFN production 
upon activation of TLR7, TLR8 and TLR9. It interacts with IRF7 and IRF5 and is 
necessary for their activation (127, 128). 
 Recently, the crystal structure of a complex consisting of the death domains of 
MyD88, IRAK4 and IRAK2 has been resolved (129). These three proteins are present in 
a ternary complex consisting of 6 MyD88, 4 IRAK4 and 4 IRAK2 molecules. These 
oligomeric structures have been named “Myddosomes” by the authors (129). According 
to Lin et al., the assembly of the Myddosome is a sequential process. While the MyD88 
death domain by itself is able to form oligomers at high concentration, IRAK4 and 
IRAK2 death domains are monomeric in solution. However, in the presence of MyD88, 
IRAK4 is oligomerized and forms a complex with oligomeric MyD88. This then acts as a 
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platform for recruitment of IRAK2 (or IRAK1). The authors believe that this hierarchical 
assembly is essential for bringing the IRAKs into a proper conformation for their 
phosphorylation and activation 
A splice variant of MyD88 has been described that acts as a negative regulator of 
MyD88-dependent signaling (130). It lacks the intermediate region and thus fails to 
recruit IRAK-4, thereby inhibiting NF-κB activation. In addition, a member of the IL-1R 
family, ST2, can sequester MyD88 and interfere with TLR4 signaling (131). IRAK-M is 
another death domain containing protein that acts as a negative regulator of MyD88 
signaling by preventing the dissociation of IRAK1 and IRAK4 from MyD88 (132).  
MyD88 thus acts as an important point of control for signaling by various receptors. 
  
Mal (MyD88 adapter-like) [also called TIR domain-containing adapter protein 
(TIRAP)]: Mal was the second TIR domain-containing adapter to be discovered. Two 
groups simultaneously identified Mal in database searches for TIR domain containing 
proteins (133, 134). The gene TIRAP is mapped to Chromosome 11. Alternative splicing 
of Mal generates two predominant isoforms of Mal in humans.  Variant  2  has  an additional segment within the 5' UTR and differs in the 3' coding region and 3' UTR, compared  to  variant  3.  This  results  in  a  longer  isoform  (b)  with  a  distinct  C‐terminus,  compared  to  isoform  a.  Variant  3  represents  the  longer  transcript  but encodes the shorter isoform (a).  Mal was discovered based on its importance for TLR4 
signaling but not IL-1 signaling. Reports by Fitzgerald et al. and Horng et al. 
demonstrated that a proline to histidine mutation in the TIR domain of Mal results in loss 
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of TLR4 signaling, but does not affect IL-1 signaling (133, 134). Additionally, Mal-
deficient mice were found to be defective in TLR4 and TLR2 signaling, but TLR9 and 
IL-1 signaling were normal (135, 136). This led to the conclusion that Mal is required for 
TLR2 and TLR4 signaling only. Mal deficient mice exhibit complete impairment of 
TLR2 mediated responses. In the case of TLR4 stimulation, these mice have a similar 
phenotype to MyD88-deficient mice/cells displaying delayed NF-κB and MAPK 
activation, thus placing Mal in the MyD88 pathway. Disease models in Mal-deficient 
mice reveal a role for Mal in early immune responses to E.coli and LPS in the lung (137). 
Mal is also important for the induction of anti-microbial peptides in the lung, in response 
to Klebsiella pneumoniae as well as LPS-induced airway hyper-reactivity (138).  
 Mal is a 235 amino acid protein with a TIR domain at its C-terminus. It lacks the 
death domain present in MyD88. It interacts with the receptors TLR2 and TLR4 as well 
as the adapter MyD88 via TIR-TIR interactions and is also capable of homodimerization 
with itself (133). Mal has a phosphatidylinositol-4, 5-bisphosphate (PIP2) binding 
domain at its N-terminus, through which it is recruited to the cell membrane (139). 
MyD88 is unable to bind TLR4 or TLR2 and thus Mal brings MyD88 to the receptor 
complex, thus acting as a bridge between the receptor and the downstream adapter 
MyD88. It has been suggested that the sole function of Mal is to recruit MyD88. 
Recently, however new properties of Mal have been revealed, with functions other than 
merely the recruitment of MyD88. Mal has a TRAF6 binding domain, via which it may 
help to recruit TRAF6 to the signaling complex (140, 141). It undergoes tyrosine 
phosphorylation by Bruton’s tyrosine kinase (Btk), which leads to increased activation of 
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p65 subunit of NF-κB (142). Moreover, at higher concentrations of TLR2 ligands, 
PAM2CSK4 or PAM3CSK4, Mal has been shown to be dispensible for TLR2 signaling 
(143). This might be due to the ability of TLR1 and TLR6 to recruit MyD88 
independently of Mal or due to a conducive surface charge potential of the TIR domain 
of TLR2 to allow for direct interactions with MyD88 TIR domain. Though Mal has no 
effect on pro-inflammatory cytokine production by TLR3, it has been shown to 
negatively influence TLR3 mediated IFN-β induction, via its ability to interact with IRF7 
(144). It also interacts with caspase-1 and cleavage by caspase-1 is an important event for 
Mal to signal (145, 146).  
  
TRIF (TIR domain-containing adapter inducing IFN):  TRIF is the sole adapter 
involved in TLR3 signaling. It also mediates the MyD88-independent arm of TLR4 
signaling (along with TRAM), leading to type I IFN induction. TRIF was identified 
independently by two groups, on the basis of its role in TLR3 signaling and in a database 
search for TIR domain containing proteins (147, 148). Like Mal and MyD88, 
overexpression of TRIF results in NF-KB activation; however only overexpressed TRIF, 
but neither MyD88 nor Mal, leads to strong induction of IRF3-dependent reporters such 
as the IFN-β gene reporter (149). The role of TRIF in TLR signaling was further 
confirmed by studies in TRIF-deficient mice. These mice were impaired in TLR3 and 
TLR4 mediated IFN-β production; while pro-inflammatory cytokine production was 
partially impaired in TLR4 but not TLR2, TLR7 or TLR9 (149).  Further evidence that 
TRIF is involved in the MyD88-independent arm of TLR4 signaling came from studies in 
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mice deficient for both MyD88 and TRIF. Cells from these mice exhibit complete 
abrogation of LPS induced NF-κB activation (150). Moreover, random germline 
mutagenesis led to the identification of the mutation Lps2 (151). The mice carrying this 
mutation were unresponsive to poly I:C and response to LPS was impaired (152, 153). 
Mice homozygous for this mutation were resistant to LPS induced shock and were more 
susceptible to cytomegalovirus (CMV) infection (153). The molecular basis for this 
mutation was a frameshift in the gene Trif. TRIF was thus established as the adapter 
controlling TLR3 as well as MyD88-independent TLR4 signaling.  
 TRIF is the largest of all the TIR adapter proteins. In addition to a central TIR 
domain, it has a receptor-interacting protein (RIP) homotypic interaction motif (RHIM) 
domain at the C-terminus. Through its RHIM domain, TRIF associates with other RHIM 
containing proteins RIP1 and RIP3 and activates Fas-associated death domain protein 
(FADD)/caspase-8 axis (154). TRIF is the only TLR adapter that can induce apoptosis 
(155).  Through its TIR domain TRIF interacts with TLR3 and with TRAM in the case of 
TLR4 signaling. The N-terminal domain of TRIF is responsible for its interaction with 
TBK1, the kinase involved in IRF3 activation (156). TRIF is also important for LPS 
induced upregulation of co-stimulatory molecules as well as MHC class II on dendritic 
cells (157).   
 
TRAM: TRAM was the fourth TLR adapter to be discovered. Like Mal and TRIF, a 
search for TIR domain containing proteins led to the identification of TRAM (158-160). 
TRAM shares sequence similarity with other TIR domain containing proteins, especially 
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with TRIF.  It is a 235 amino acid protein with a TIR domain at its C-terminus. TRAM is 
the most restricted of all adapters, involved only in the MyD88-independent axis of TLR4 
signaling. TLR4 thus involves all four adapter proteins, with MyD88/Mal signaling being 
initiated first, followed by a delayed TRIF/TRAM response. TRAM acts as a bridging 
adapter between TLR4 and TRIF, playing a role similar to Mal in this regard (160).   
 A bipartite localization motif has been identified in TRAM. The N-terminus of 
TRAM has a myristoylation motif, which is required for its recruitment to the membrane 
(161). Mutations of the myristoylation motif, lead to mis-localization of TRAM and loss 
of its signaling ability.  The myristoylation motif is followed by a stretch of polybasic 
residues. Other proteins that harbor this bipartite motif are known to shuttle between the 
plasma membrane and endosomes. Indeed, it was demonstrated that TRAM exists both at 
the plasma membrane and in the endosomal compartment (162).  Currently, it is thought 
that TLR4 first induces MyD88/Mal signaling at the membrane and is then endocytosed 
and activates TRIF/TRAM signaling from endosomes (162). 
  
SARM: SARM is a TIR domain-containing protein that also contains sterile α- (56) and 
HEAT/armadillo motifs (ARM) (163). However, it is not considered an adapter protein in 
the same sense as the other four adapters. The first studies on SARM revealed that in 
contrast to the other four TLR adapters, SARM was unable to induce NF-κB activation. It 
is now considered a negative regulator of NF-κB and IRF activation (164). It specifically 
inhibits TRIF-mediated gene induction, but has no effect on MyD88-dependent pathway 
or non-TLR signaling (164).  LPS stimulation leads to an increase in SARM protein 
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levels, suggesting a negative feedback of the TRIF mediated pathway. Both the TIR and 
the SAM domains are necessary for this effect. SARM interacts directly with TRIF and 
this may be a mechanism by which SARM exerts its inhibitory effects. The interaction 
between TRIF and SARM may prevent the recruitment of the downstream signaling 
components like TBK1 and TRAF6. Another mechanism of inhibition might be through 
the recruitment of an inhibitory protein via its SAM motifs. 
 
Interleukin-1 receptor-associated kinases (IRAKs) 
Interleukin-1 receptor-associated kinases (IRAKs) are a family of intracellular 
kinases with an important role in the innate immune pathways (165). There are four 
IRAK members: IRAK1, IRAK2, IRAK-M and IRAK4. Human IRAK1, IRAK2 and 
IRAK4 are ubiquitously expressed, whereas IRAK-M is expressed in an inducible 
manner in monocytes and macrophages only. All IRAKs have a similar domain structure. 
At their N-terminus is a death domain (DD), followed by a proST region that is rich in 
prolines, serines and threonines, a central conserved kinase domain and a C-terminal 
domain that is absent in IRAK4. The death domain is responsible for interactions with 
other death domain containing proteins like MyD88 (166). The central kinase domain 
contains an activation loop that is essential for kinase activity. The C-terminal domain is 
responsible for interaction with TRAF6; IRAK1, IRAK2 and IRAK-M have three, two 
and one TRAF6 interaction motifs respectively (167). 
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IRAK1: IRAK1, the first IRAK family member to be discovered is a 712 amino 
acid protein, initially shown to have a role in IL-1 signaling (165, 168). It undergoes 
phosphorylation on critical threonine residues in the kinase domain as well as 
hyperphosphorylation in the proST region (169). Phosphorylation and activation of 
IRAK1 are followed by K-48 linked ubiquitination, leading to the degradation of IRAK1 
(170). Cells from IRAK1 deficient mice exhibit reduced but not completely ablated 
TLR/IL-1R dependent NF-κB, MAPK and cytokine induction (171, 172). The kinase 
activity of IRAK1 is not essential for NF-κB activation but is implicated in TLR7 and 
TLR9 induced IFN-α production (173). It has also been shown to interact with TRAF3, a 
vital player in TLR induced type I IFN production (174). 
IRAK2:  The second IRAK to be identified was IRAK2, a 590 amino acid protein 
that shares sequence similarity to IRAK1 (126, 175). The role of IRAK2 in TLR 
signaling was examined using macrophages from IRAK2 deficient mice (176). These 
studies demonstrated that IRAK2 functions redundantly with IRAK1 in signaling and 
only when IRAK2 deficient mice were crossed with IRAK1 deficient mice, a dramatic 
impairment in TLR signaling could be observed (177). 
IRAK-M: The third family member to be identified was IRAK-M, a 596 amino 
acid protein with unique features (178, 179). It is the only member of the IRAK family to 
lack kinase activity and has been reported to function as a negative regulator (132, 180). 
Macrophages from IRAK-M deficient mice, exhibited increased TLR/IL-1R response, 
suggesting an inhibitory role for IRAK-M (180).  
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IRAK4: IRAK4 is the most recently discovered member of the IRAK family 
(181-183). It is the closest homolog of the Drosophila Pelle protein, the only known 
IRAK in the fly. Unlike IRAK-1, mice deficient in IRAK4 are unable to mount a 
cytokine response to various TLR ligands (184). In addition, they are completely resistant 
to LPS-induced septic shock (184). IRAK4 interacts with MyD88 via its death domain 
and this interaction is necessary for NF-κB activation (130). It is also responsible for 
phosphorylating IRAK1, which leads to the autophosphorylation and activation of 
IRAK1 (185). IRAK4 has also been shown to have an important role in type I IFN 
production by TLR7/8/9 (186). However, it is dispensable for MyD88-independent or 
TRIF mediated TLR responses. 
 
TLR4 signaling pathway 
Amongst all the TLRs, TLR4 is unique in utilizing all four TIR domain-containing 
adapters. TLR4 recognizes lipopolysaccharide or LPS from the cell walls of bacteria. 
Lipopolysaccharide (LPS):  LPS is a major component of the outer membrane of Gram-
negative bacteria and plays an important role in maintaining the structural and functional 
integrity of the bacterial membrane. LPS has three components: lipid-A, core-
oligosaccharide and O-antigen (or O-polysachharide) (187). The highly hydrophobic 
lipid-A moiety is chiefly responsible for the endotoxic activity of LPS. Core 
oligosaccharide is a short chain of sugar residues that attaches directly to lipid-A and is 
highly variable among bacterial species. O-antigen is a highly variable region composed 
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of saccharidic units repeated a number of times (188). It is attached to core-
oligosaccharide and is the outermost domain of LPS molecule. Since O-polysaccharide 
can also be targeted by antibodies, it is also known as O-antigen. Depending on the 
presence or absence of O-polysaccharide, LPS can be classified as “smooth” or “rough” 
LPS respectively. 
Initiation of signaling: Even though TLR4 is the signal transducing component of the 
LPS recognition complex, a 25 kDa co-receptor known as Myeloid Differentiation-2 
(MD-2), is also absolutely required for LPS signalling. Two additional extracellular 
accessory proteins are needed for full responses to LPS. They are a 60 kDa serum LPS-
binding protein (LBP) and a 55 kDa LRR protein designated as CD14. The chief function 
of LBP is to monomerize LPS from bacterial membranes and make it readily available to 
CD14 (189, 190).  CD14 is a glycosylphosphatidylinositol (GPI)-anchored protein that 
accepts LPS monomers from LBP and transfers them to TLR4:MD-2 complex, inducing 
its dimerization (191, 192). TLR4 does not directly bind LPS. Instead MD-2, which 
exists in a complex with TLR4 is responsible for binding the lipid-A moiety of LPS 
(193).  Ligand binding induces conformational changes to bring about dimerization of the 
TLR4:MD-2 complex. 
 
MyD88-dependent and independent signaling pathways: Upon binding LPS, two 
pathways are initiated: MyD88-dependent and MyD88-independent or the TRIF-
dependent pathway (FIG I.3). 
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MyD88-dependent pathway  
LPS binding to the MD-2-TLR4 complex initiates a signaling cascade. Upon 
activation, TLR4 is thought to relocate and cluster to lipid rafts (194). TLR4 dimerization 
induces conformational changes in its TIR domain creating sites for the binding of 
Mal/TIRAP, which is normally localized to the PIP2 rich regions of the membrane. Mal, 
then engages MyD88 through TIR-TIR interactions. In light of the recent finding 
describing the Myddososme, MyD88:IRAK4:IRAK1 complex might be preformed in the 
cytosol and recruited to the receptor complex upon activation. Conversely, MyD88 might 
bind to Mal first and then assemble the Myddosome at the receptor complex. Once 
MyD88, IRAK4 and IRAK2 are at the receptor complex, IRAKI undergoes 
phosphorylation by IRAK4 on threonine residues. This activates autophosphorylation of 
IRAK1 that leads to its activation and subsequent dissociation from the complex. IRAK1 
then interacts with TNF receptor-associated factor 6  (TRAF6), an E3 ubiquitin ligase 
that catalyses the addition of Lys63 (K63) linked chains on target proteins, including 
TRAF6 itself and IRAK1. The TRAF6-IRAK1 complex then interacts with a preformed 
TAK1 (transforming growth factor β-activated-kinase 1)-TAB1 (TAK1-binding protein)-
TAB2 complex. The polyubiquitin chains bind to TAB2 and TAB3 and activate the 
kinase TAK1 (195). The K63 chains also bind to NEMO, a regulatory component of the 
IKK complex, thus bringing the IKK complex in proximity to TAK1 (196). 
Phosphorylation and activation of IKK (IκB kinase) proteins (possibly by TAK1), is 
followed by phosphorylation of inhibitor of κB (IκB). IκB then undergoes K48-linked 
polyubiquitination and finally degradation, allowing NF-κB to translocate to the nucleus 
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and induce gene transcription.  
TRAM-TRIF dependent pathway  
The MyD88-independent or the TRIF mediated pathway downstream of TLR4 is 
responsible for the delayed NF-κB activation as well as type I IFN production via IRF3 
activation. MyD88 dependent and independent pathways are not triggered simultaneously 
upon LPS activation, but rather in a sequential manner. Upon binding of LPS to the 
TLR4-MD-2 complex, the Mal-MyD88 pathway is first initiated leading to pro-
inflammatory cytokine production described above. The receptor complex is then 
endocytosed and delivered to the endolysosomes where TRAM and TRIF are recruited 
and signaling is initiated (158). TRIF then interacts with RIP1 via its RHIM domain. 
RIP1 then binds E3 ubiquitin ligase TRAF6 that catalyzes K63-linked polyubiquitination 
of RIP1. K63 chains of RIP1 help to recruit NEMO to the complex as well as TAK1. 
TAK1 activates the IKK complex leading to NF-κB and MAPK activation resulting in 
pro-inflammatory cytokine induction. On the other hand, IFN production by TRIF 
depends largely on its interaction with TRAF3 and subsequent K63-linked ubiquitination 
of TRAF3. This helps in recruiting TANK (TRAF family associated NF-κB activator) 
(197). This then allows the IKK related kinases TBK1 and IKKε to phosphorylate IRF3 
and induce the type I IFN response (198). 
 The discovery of sequential initiation of the Mal-MyD88 and TRAM-TRIF signal 
transduction pathways presents a new model for initiation of TLR4 signaling. Initial LPS 
recognition by TLR4 leads to recruitment of the receptor to the PIP2-rich lipid rafts 
where the TIR domain of TLR4 engages the TIR domain of Mal, ultimately leading to the 
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early wave of NF-κB activation. LPS stimulation is shortly followed by dynamin-
dependent TLR4 and CD14 endocytosis. The endocytosis of the receptor complex leads 
to dissociation of Mal from the TIR domain of TLR4, leaving the TIR domain of TLR4 
available for interaction with TRAM to cause type I IFN induction. This two step 
activation pathway enables the categorization of the TRIF mediated TLR4 signaling with 
the other known endosomal TLRs that lead to IFN production. The functional separation 
of TLRs into pro-inflammatory cytokine or IFN inducers thus correlates with the spatial 
separation of cell surface or endosomal TLRs respectively. 
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FIGURE I.3: TLR4 signaling pathway:  LPS binding to the TLR4-MD2 complex 
induces two pathways. MyD88-dependent pathway is triggered first, leading to NF-kB 
activation and pro-inflammatory cytokine production. The internalized receptor complex 
induces the TRIF-TRAM dependent pathway from the endosomes leading to TRAF6 
mediated NF-κB activation as well as TBK1 and IKKε dependent IRF3 activation. 
 
35 
FIGURE I.3 TLR4 signaling pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
Single Nucleotide Polymorphisms (SNPs) 
Two randomly selected individuals share 99.9% similarity in their DNA sequence 
(199). The remaining 0.1% sequence that is variable or polymorphic between individuals 
arises because of mutation. The difference between a mutation and a polymorphism lies 
in its frequency in the population. When a mutation is prevalent in the population at a 
frequency higher than 1 %, it is called a polymorphism (200). The simplest and most 
basic of all polymorphisms is a single base change in the DNA called single nucleotide 
polymorphisms or SNP. SNPs are the most ubiquitous and the most frequently occurring 
of all polymorphisms. It is estimated that they occur at a frequency of 1 in about 1,000 
base pairs. SNPs can be found in exons, introns, promoter regions, intergenic regions, etc. 
A SNP within the coding region may or may not change the corresponding amino acid 
due to the degeneracy of the codon usage. When a SNP does not change the amino acid 
of the protein, it is called a synonymous SNP, in contrast to a non-synonymous SNP that 
leads to a change in the amino acid sequence. Instead of a base change, SNPs can 
sometimes insert or delete a base, thus leading to a frame shift in the protein sequence. 
Moreover, a non-synonymous SNP may generate a STOP codon, causing premature 
termination and truncated or inactive proteins. Such polymorphisms are called nonsense 
SNPs.  
SNPs in the non-coding regions usually have no effect on the phenotype. 
Sometimes however, SNPs in the introns may be present in close proximity to the splice 
junctions, affecting appropriate splicing of the encoded protein (201). Also, base changes 
in the promoter region may affect the expression of the gene and those in the untranslated 
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regions of the gene may influence mRNA stability (202-204). On the other hand, not all 
non-synonymous SNPs lead to appreciable protein changes. An amino acid may be 
replaced by another amino acid with very similar structure and chemical properties, in 
which case, the protein may still function normally; this is termed a neutral, "quiet", or 
conservative mutation. Alternatively, the amino acid substitution could occur in a region 
of the protein that does not significantly affect the protein secondary structure or 
function.  
Genetic variation affects predisposition to disease 
Variation in the DNA sequence can affect how an individual develops disease, 
responds to pathogens or other environmental factors (205, 206). Perhaps the most well 
characterized example of a SNP leading to a profound change in the phenotype of an 
organism is sickle cell anemia. A base change from A to T encodes a Valine instead of a 
Glutamate residue in the β-globin gene . This single residue change affects the shape of 
the β subunit of hemoglobin making the red blood cells carrying the aberrant hemoglobin 
sickle shape in appearance instead of the characteristic disc shaped.  
TLR signaling leads to the induction of a large number of genes through multiple, 
finely coordinated steps in order to appropriately respond to the pathogen. Preserving 
structural integrity of the TLR signaling components is thus essential to maintain 
immunologic protection. Any changes in the structure of the many signaling molecules 
involved in the pathway, could affect the final outcome of the cascade. Changes in the 
structure can sometimes be due to SNPs in the coding region.  
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 Many instances of molecular changes in the TLR signaling pathway have been 
described, often with dramatic outcomes. The two most well-studied SNPs in TLR 
signaling are Asp299Gly and Thr399Ile in TLR4 (207). These two co-segregating 
polymorphisms in the extracellular domain of TLR4 are present at a frequency of 10% in 
Caucasians and have been associated with hyporesponsiveness to LPS (207-209). Since 
they are present in the extracellular domain of TLR4, they are predicted to affect the 
binding of the ligand. Asp299Gly has been demonstrated to have a greater functional 
impact than Thr399Ile (207). These two SNPs have been associated with severe respiratory syncytial virus (RSV) bronchiolitis  in  infants (210). Another study also saw  a  correlation  between  the  Thr399Ile  SNP  and  increased  colonization  of pregnant women with Gardnerella sp. and other Gram‐negative commensals (211). On  the  other  hand,  two  studies  failed  to  detect  a  significant  correlation  between these two SNPs and the incidence of sepsis after surgery as well as severity of severe inflammatory response syndrome (212, 213).  
Other studies have highlighted the impact of SNPs on protein function and the 
predisposition to disease. A common STOP codon polymorphism in the signaling domain 
of TLR5 completely ablates signaling through TLR5 and increases the susceptibility of 
the individuals carrying this polymorphism to Legionnaire’s disease (214). The same 
polymorphism has been associated with increased resistance to systemic lupus 
erythematosus (SLE) (215). More than one mutation in the IRAK-4 gene has been 
reported to lead to a truncated form of the gene and individuals harboring these SNPs are 
inflicted with recurrent pyogenic bacterial infections (216, 217). Thus, variation in innate 
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immune genes may not only affect the function of the protein, but might have a bearing 
on the outcome of various diseases too. 
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Thesis Objective and Summary 
Toll-like receptors (TLRs) are the key sensors of microbial infection in mammals. At the 
core of TLR signaling are the TIR domain-containing adapters: signaling proteins that not 
only provide specificity to the TLR pathways, but are imperative for the signaling to 
ensue. The structural integrity of the TLR signaling components, especially the TIR 
adapters, is thus essential to maintain immunologic protection. The work done in this 
thesis addresses the molecular perturbations that can be brought about by single 
nucleotide polymorphisms (SNPs) in the coding region of adapter proteins. The main 
focus is on the adapters Mal and MyD88, which are the most polymorphic amongst all 
the adapter proteins and thus are good candidates for this study. I test the hypothesis that 
coding SNPs in the adapters Mal and MyD88 can change the signaling capability of these 
proteins using diverse biochemical approaches and attempt to provide a structure-
function relationship for the loss-of-function phenotype observed in each case. In 
addition to providing unique insights into the structure of the adapter proteins Mal and 
MyD88, the work presented here characterizes two naturally occurring loss-of-function 
mutations that, though rare in the population, might still affect predisposition to various 
life-threatening diseases in some individuals. Moreover, by delineating the amino acids 
absolutely essential for signaling, this thesis brings to light potential novel drug targets 
for the treatment of a number of inflammatory and autoimmune diseases. 
Chapter II: A TIR domain variant of Mal/TIRAP results in loss of MyD88 binding 
and reduced TLR2/TLR4 signaling. This chapter focuses on D96N, a TIR domain 
polymorphism in the adapter Mal that is completely inactive in TLR2 and TLR4 
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signaling. The reason for this defect is the inability of Mal D96N to bind the downstream 
adapter MyD88, an event that is essential for signaling to occur. 
Chapter III: A natural loss-of-function mutation of MyD88 disrupts its ability to 
form Myddosomes: This chapter describes a death domain mutant of MyD88, S34Y, 
which is severely comprised in its ability to respond to all MyD88 dependent ligands.  
MyD88 S34Y has a noticeably different localization pattern than wild type MyD88 and is 
unable to form signaling complexes called Myddosomes with IRAK4 and IRAK2.  
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                              PREFACE TO CHAPTER II 
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Nagpal, K., 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Wong, 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Monks, 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Gay, 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CHAPTER II 
 
 
 
 
A TIR DOMAIN VARIANT OF MAL/TIRAP RESULTS IN LOSS OF MYD88 
BINDING AND REDUCED TLR2/TLR4 SIGNALING 
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Abstract 
The adapter protein MyD88 adapter-like (Mal), encoded by TIR-domain 
containing adapter protein (Tirap) (MIM 606252), is the most polymorphic of the five 
adapter proteins involved in Toll-like receptor (TLR) signaling, harboring eight non-
synonymous single nucleotide polymorphisms (SNPs) in its coding region. We screened 
reported mutations of Mal for activity in reporter assays in order to test the hypothesis 
that variants of Mal existed with altered signaling potential. A TIR domain variant, Mal 
D96N (rs8177400), was found to be inactive. In reconstituted cell lines, Mal D96N acted 
as a hypomorphic mutation, with impaired cytokine production and NF-kB activation 
upon LPS or PAM2CSK4 stimulation. Moreover, co-immunoprecipitation studies 
revealed that Mal D96N is unable to interact with MyD88, a prerequisite for downstream 
signaling to occur. Computer modeling data suggested that residue 96 resides in the 
MyD88 binding site, further supporting these findings. Genotyping of Mal D96N in three 
different cohorts suggested that it is a rare mutation. We thus describe a rare variant in 
Mal that exerts its effect via its inability to bind MyD88.  
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Introduction 
The adapter protein Mal/TIRAP  (hereafter referred to as Mal) is involved in the 
MyD88-dependent pathway downstream of TLR2 and TLR4 (133, 134). It acts as a 
bridging adapter between the receptor and the sorting adapter MyD88 (139). The 
receptors TLR2 and TLR4 as well as MyD88, all have a predominantly electropositive 
surface, preventing MyD88 to bind to the receptor (218). Mal, on the other hand has a net 
electronegative surface charge, thus being able to interact with the receptor (TLR2 or 
TLR4) and recruiting MyD88 to the complex. Upon activation of TLR2 or TLR4, a 
signaling cascade is initiated, which leads to the activation of transcription factors such as 
Nuclear Factor-kappa B (NF-κB), Interferon Regulatory Factor (IRF)-5 and Activator 
Protein (AP-1), ultimately culminating in the production of pro-inflammatory cytokines 
(219). However, an uncontrolled inflammatory process can be detrimental to the host and 
thus in mammals a number of mechanisms have evolved to attenuate and regulate the 
TLR pathways. TIR domain containing adapters are also subjected to such regulation. 
During TLR2 and TLR4 signaling, Bruton’s tyrosine kinase (Btk) phosphorylates Mal at 
three residues (142). Phosphorylated Mal can then interact with suppressor of cytokine 
signaling-1 (SOCS-1), resulting in Mal polyubiquitination and subsequent degradation 
(220). A recent report by Dunne et al. demonstrates that Mal can be phosphorylated by 
both IRAK-1 and IRAK-4 and this promotes its ubiquitination and degradation (221). 
Cleavage of Mal by caspase-1 is another event necessary for NF-κB activation by Mal 
(145). Mal is thus subjected to multiple regulatory mechanisms and as such serves as 
another level of control for TLR2 and TLR4 signaling. 
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The importance of Single Nucleotide Polymorphisms (SNPs) in TLR related 
proteins and their association with various infectious and inflammatory diseases have 
recently emerged (222, 223). One of the earliest studies on polymorphisms in adapter 
proteins demonstrates that a SNP in Mal, A186A is associated with increased 
susceptibility to meningeal tuberculosis (222). A study by Hill et al. reported that 
individuals heterozygous for the polymorphism S180L in Mal are protected against 
pneumococcal disease, bacteremia, malaria and tuberculosis (224).  They further show 
that S180L leads to reduced TLR2 signaling and the reason for this defect is the inability 
of Mal S180L to bind TLR2. Within the coding region of a gene, SNPs can alter the 
characteristics and affect the ability of a protein to function (225). Interestingly, Mal is 
the most polymorphic of all adapter proteins, harboring at least 8 non-synonymous 
variants in its coding region. It thus appears to be an important candidate for studying 
genetic variation in relation to TLR2 and TLR4 signaling. 
In the present study, we characterized the known polymorphisms in the coding 
region of Mal for effects on the function of Mal (FIG II.1). We report that one of the 
mutations in the TIR domain of Mal, D96N, is broadly defective in TLR2- and the 
MyD88 branch of the TLR4 signaling pathway. We show by biochemical and computer 
modeling data that the basis of this abnormality is the inability of Mal D96N to bind 
MyD88.  While the incidence of this lesion in humans is not known, we screened three 
small populations for the defect and found a single heterozygous individual, suggesting 
that D96N is a rare mutation. We thus identify a mutation in Mal that causes a structural 
change, affecting the ability of the protein to bind the downstream effector MyD88. 
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FIGURE II.1: Domain structure of Mal 
 
 
 
 
 
 
 
 
 
 
FIGURE II.1: Domain structure of Mal: A schematic showing the positions of the 
SNPs in the coding region of Mal. 
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Experimental procedures 
Plasmids and site directed mutagenesis: Most of the constructs described in this work 
have been described elsewhere. These include: pEF-BOS-Mal-FLAG (198); pCDNA3-
MyD88CFP (106); pCMV-IRF5-FLAG (226), NF-κB-luciferase, ISRE-luciferase, and 
Renilla-luciferase (158); and the retroviral vector pMSCV2.2-IRES-GFP (FIG II.2) 
(227). pEF-BOS-Mal-FLAG and pMSCV2.2-IRES-GFP-human-Mal with the different 
mutations in the TIRAP gene were generated by using a site-directed mutagenesis kit 
Quickchange (Stratagene), per the manufacturer’s instructions.  
Generation of wild type and Mal-deficient immortalized macrophage-like cell lines: Bone 
marrow cells were isolated from the femurs of wild type or Mal deficient mice. After red 
blood cell (RBC) lysis, cells were resuspended in 2.5 ml of filtered supernatant of 
ΨCRE-J2 cells (as the source of the recombinant retrovirus J2 with the oncogenes v-raf 
and v-myc ) supplemented with 1.25 ml of DMEM and 1.25 ml of L929 conditioned 
supernatant (as the source of M-CSF) (228). Next day, supernatants were removed and 
cells were cultured in fresh DMEM supplemented with 20% L929 supernatants. After 
eight days, supernatants were removed and cells were cultured in medium without growth 
factors. The polyclonal population of immortalized cells were then cloned by limiting 
dilution method and the clones were tested based on a number of characteristics. 
Transduction of immortalized macrophage-like cell line with recombinant retroviruses: 
FLAG-tagged human Mal (WT) or the different variants of Mal were cloned into the 
retroviral vector pMSCV2.2-IRES-GFP (FIG II.2) (227). HEK293T were plated in a 6-
well plate at a density of 5x105 cells per well. Next day the cells were tranfected with the 
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retroviral construct (300 ng/well), and the packaging vectors encoding gag-pol (300 
ng/well) and VSV-G (30 ng/well) using genejuice. While “gag” encodes the capsid 
proteins, “pol” is responsible for encoding the reverse transcriptase and integrase 
proteins. VSV-G protein enables viral entry, by promoting attachment of the virus to the 
cell, allowing it to be endocytosed. It is also responsible for the broad tropism exhibited 
by VSV-G pseudotyped viruses.  Two wells were used for each Mal variant transfection. 
Sixteen hours later, transfection reagent containing media was changed with fresh media. 
After 48 hours, supernatants containing viral particles were collected, passed through 
0.45 µ syringe filter and added to previously plated Mal-deficient immortalized 
macrophages in a T25 flask. A week later the bulk population was subjected to FACS 
(fluorescence associated cell sorting) to select positively transduced cells based on the 
expression of GFP from the IRES element. The cells were allowed to recover for a few 
days and then cloned by limiting dilution to give rise to single cell clones. Equal 
expression of Mal or the Mal variants in selected clones was confirmed by western 
blotting with anti-FLAG antibody. 
Luciferase reporter assay: HEK293T cells were seeded into 96-well plates at a density of 
20,000 cells per well and transfected 16 h later with 40 ng of the indicated luciferase 
reporter genes and the indicated amounts of Mal (wt or polymorphic) with IRF-5 (10ng) 
construct using GeneJuice (EMD Biosciences, San Diego). The thymidine kinase Renilla-
luciferase reporter was co transfected (40 ng) to normalize the data for transfection 
efficiency. Two days later reporter gene activity was measured using the Dual Luciferase 
Assay System (Promega, CA, USA). 
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FIGURE II.2: Retroviral vector pMSCV2.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE II.2: Retroviral vector pMSCV2.2: Vector map of the retroviral construct 
used for reconstitution of the Mal deficient immortalized cell line. FLAG-tagged Mal 
(WT) or the different variants of Mal were cloned into the vector using Xho I and Not I 
restriction sites. GFP translated from the IRES site was used for selecting the positively 
transduced cells. 
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ELISA: Cells were seeded into 96-well plates at a density of 20,000 cells per well and 
stimulated overnight with the indicated concentrations of the TLR ligands.  Cell culture 
supernatants were assayed for TNFα with ELISA kits from R&D systems, according to 
the manufacturer's instructions. 
Quantitative Real-Time PCR: Wild type, Mal deficient or D96N expressing macrophages 
were plated at a density of 2x106 cells per well in a 6-well plate. They were stimulated 
with 100 ng of LPS/ml for 2 hrs. RNA extraction and IFN-β mRNA induction analysis by 
quantitative Real-Time PCR was carried out as described elsewhere (229). 
IkB degradation assay: 2x106 Cells were seeded per well into a 6-well plate. After 24 hrs, 
the cells were treated with 10 nM PAM2CSK4 or 100 ng/ml LPS for the indicated time 
intervals. Cell lysates were made and run on an 8-16% SDS gel (NuSep, GA, USA), 
transferred to nitrocellulose membrane and probed with anti-IkB. (Cell Signaling 
Technology, MA, USA). 
Immunoprecipitations and immunoblots: HEK293T cells were transfected with TLR2-
YFP, TLR4-CFP or MyD88-CFP and FLAG-tagged Mal (WT or D96N) using genejuice 
transfection reagent. Two days post-transfection, cells were harvested and the lysates 
were incubated overnight with polyclonal anti-GFP antibody (Invitrogen, CA, USA) and 
Poly-A Sepharose beads. Rabbit IgG was used as a control. The processed samples were 
run on an SDS gel, transferred to nitrocellulose membrane and probed with an HRP 
conjugated anti-FLAG antibody (SIGMA, MO, USA).  The immunoprecipitation of 
TLR2-YFP, TLR4-CFP and MyD88-CFP was checked by immunoblotting the same 
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membrane with monoclonal anti-GFP antibody (Invitrogen, CA, USA). Expression level 
of the proteins in whole cell lysates was checked by immunoblotting with HRP 
conjugated anti-FLAG antibody and monoclonal anti-GFP antibody. 
Molecular modelling of Mal D96N: The amino acid sequences and three-dimensional 
structures of the TIR domains of TLR1 and TLR2, homologous proteins used as 
templates for comparative modelling, were obtained from the Protein Data Bank 
(http://www.rcsb.org/pdb). Initial alignments between Mal and its templates were 
obtained using the program FUGUE (230).  Models were produced using the program 
MODELLER (231) as previously described  (232). Site Directed Mutator (233) was used 
to calculate a stability score for a specific point mutation (96N) in the Mal TIR model. 
3D structure visualization and image generation was carried out using Pymol (DeLano, 
W. (2002) DeLano Scientific, Palo Alto, CA, USA). 
Confocal Microscopy Imaging:  HEK293T cells were seeded in 35-mm glass bottom 
tissue culture dishes (Mat Tek Corporation, MA, USA) at a density of 250,000 cells per 
dish. Next day, the cells were transiently transfected with the indicated plasmids. 
Twenty-four hours later, live cells were imaged on a Leica SP2 AOBS confocal laser-
scanning microscope.  
Genotyping of TIRAP D96N in human subjects: Genetic studies were approved by the 
Ethical Committee of the Radboud University Nijmegen, The Netherlands.  Genomic 
DNA from 91 African Tanzanians, 97 Chinese Han and 188 Caucasian Dutch individuals 
(234) were screened for the presence of TIRAP D96N (which encodes for Mal D96N).  
Screening was performed by PCR amplification and sequencing.  For amplification, the 
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forward primer 5’-AGTGAGAGGGCACCTGGTAA-3’ and the reverse primer 5’- 
CACAGCTCGGACACTATAGCGCC-3’ were used. Sequencing was performed with 
the same primers on a 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA) 
by the DNA Sequencing Facility, Radboud University. 
Results 
Transient expression of D96N does not activate NF­κB and ISRE reporters: The non‐synonymous SNPs occurring in the coding region of human Mal were selected from the NCBI SNP database. These were examined for their ability to drive two signaling pathways known to function downstream of Mal. Transient expression of WT Mal in HEK293T  cells  triggers  activation  of  NF‐κB  and  IRF‐5‐dependent  interferon stimulated response element (ISRE) luciferase reporters (145, 235).   Notably, IRF5 is  activated  downstream  of  Mal  and  MyD88,  but  not  TRIF  or  TRAM  (235).  As expected,  WT  Mal  could  drive  both  reporters.  Moreover,  four  of  the  five polymorphisms screened were comparable to wild‐type Mal in their ability to drive both reporters (FIG II.3). However, Mal D96N was severely compromised in driving either the NF‐κB (FIG II.3A) or the IRF5‐ISRE (FIG II.3B) reporter. IRF5 by itself can weakly activate the ISRE reporter, but the co‐expression of wild type Mal leads to a much greater activation above this background value (FIG II.3B). In the case of Mal D96N, this increase in activity over the background level was not seen. These results suggest that Mal D96N does not drive signal transduction upon over expression. 
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FIGURE II.3: D96N is unable to drive either NF-κB or IRF5-dependent ISRE 
reporter 
 
 
 
 
 
 
 
 
FIGURE II.3:  Human Mal (hMal) carrying the D96N mutation is unable to activate 
either NF-κB or IRF-5. HEK293T cells were transfected with different variants of Mal 
and either NF- κB luciferase (A) or IRF-5 and ISRE-luciferase reporters (B). 48 hrs post-
transfection, lysates were analyzed for luciferase activity. Renilla-luciferase activity was 
used to normalize for transfection efficiency. Results are reported as the mean of 
triplicate determinations ± SD. Each graph is representative of three (A) or two (B) 
independent experiments. RLU: Relative Luciferase Units. 
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The immortalized macrophage-like cell lines retain the characteristics of primary 
macrophages: In order to study these polymorphisms in phagocytes with a clean genetic 
background, we immortalized bone marrow derived macrophages (BMDM) from wild-
type and Mal-deficient mice using a retrovirus encoding several oncogenes (228). The 
single cell clones obtained were characterized based on three criteria: morphology, 
surface marker expression and functional response to TLR ligands. The immortalized 
macrophages had a similar morphology as compared to primary macrophage culture. FIG 
II.4A shows wild type immortalized macrophages (left panel) with the primary 
macrophages (right panel). CD11b and F4/80 are the pan macrophage markers. 
Expression of these two surface markers was analyzed for both primary as well as 
immortalized wild type macrophages (FIG II.4B). Like the primary cells, immortalized 
macrophages expressed high levels of both CD11b and F4/80. Importantly, they were 
negative for CD11c, which is a pan dendritic cell marker. The cell lines were stimulated 
with the indicated TLR ligands and the levels of TNF-α in the supernatants was assessed. 
Immortalized wild type and Mal-deficient macrophage-like cell lines had a similar 
response pattern as their primary cell counterparts (FIG II.4C). 
The expression of WT Mal functionally complements Mal-deficient macrophages: We 
generated retroviruses expressing FLAG-tagged wild type Mal in tandem with an internal 
ribosomal entry site (IRES)-encoded green fluorescent protein (GFP) (FIG II.2). This 
construct expresses a bicistronic mRNA that allows the translation of both Mal and GFP 
in the Mal-deficient immortalized cell line. The transduced cells were sorted for GFP and  
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FIGURE II.4: Characterization of immortalized macrophage-like cell lines. 
Immortalized macrophage-like cell lines from wild-type and Mal knockout mice retain 
the characteristics of bone marrow derived macrophages. J2 recombinant retrovirus was 
used for generating immortalized macrophage cell lines. Macrophage phenotype was 
verified by morphology (A), surface expression of the markers CD11b and F4/80  (B) as 
well as functional responsiveness to a panel of TLR ligands (C). The cells were treated 
overnight with the indicated ligands. Supernatants were subsequently analyzed for the 
presence of TNF-α by ELISA. Results are reported as the mean of triplicate 
determinations ± SD. 
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FIGURE II.4: Characterization of immortalized macrophage-like cell lines 
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then cloned by limiting dilution. In Mal-deficient macrophages, TNF-α production in 
response to LPS was significantly reduced whereas in response to PAM2CSK4, it was 
completely abrogated. We examined TNF-α production in the clone obtained from 
transducing Mal-deficient cell line with retrovirus expressing WT Mal. The single cell 
clone could completely restore responsiveness to LPS and PAM2CSK4 stimulation (FIG. 
2.5A). Similarly, cells lines expressing each of the variant forms of Mal were generated. 
Clones with similar levels of expression of Mal, as assessed by Western blot, were 
selected for further study (FIG. 2.5B). 
Mal D96N has impaired cytokine production: Reconstituted cell lines were stimulated 
with LPS and PAM2CSK4 and the pro-inflammatory cytokine TNFα was measured in 
cell supernatants by ELISA. The variants A9P, R13W, S180L and V197I were fully 
functional and produced comparable levels of TNF-α as WT cells. However, in 
agreement with our earlier experiments, D96N was significantly compromised in its 
ability to produce pro-inflammatory cytokines upon stimulation (FIG II.6A). The 
production of another pro-inflammatory cytokine, IL-6 was similar to TNFα (data not 
shown). As a control, TNFα production by the double stranded RNA mimetic poly I:C 
stimulation was also measured. Poly I:C is a TLR3 ligand, whose signaling is 
independent of Mal (236).  In this case, TNFα production in cells expressing the D96N 
mutation was comparable to WT macrophages as well as to cells expressing the different 
variants of Mal. To test whether the MyD88-independent TLR4 signaling is intact in 
D96N expressing cells, we measured induction of IFN-β mRNA upon LPS stimulation,  
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FIGURE II.5: huMal is able to fully complement function in Mal-deficient 
macrophages 
(A) Functional restoration of Mal-deficient immortalized macrophage cell line. 
Immortalized Mal knockout cells were transduced with a retrovirus carrying FLAG-
tagged Mal. Single cell clones were obtained by limiting dilution and the selected clone 
was then tested for responsiveness to LPS and PAM2CSK4. WT immortalized 
macrophages, Mal-deficient macrophages as well as the cells expressing wt Mal were 
plated in a 96-well plate and stimulated overnight with LPS and and PAM2CSK4. TNF-α 
levels in the supernatants was assessed using ELISA. (B) The same strategy was used to 
generate cell lines expressing the different variants of Mal. For each cell line, clones were 
chosen for further study based on similar levels of expression of Mal or the Mal variant. 
The western blot shows the expression levels of the FLAG-tagged versions of different 
clones that were selected. 
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FIGURE II.5: huMal is able to fully complement function in Mal-deficient 
macrophages 
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FIGURE II.6: Cells expressing D96N have impaired cytokine production:  (A) 
Immortalized Mal-deficient macrophage cell lines expressing either WT Mal or one of 
the variants were stimulated with LPS, PAM2CSK4 and poly I:C overnight. The 
supernatants were then analyzed for TNF-α levels.  Poly I:C, a TLR3/TRIF ligand, was 
used as a control for Mal-independent signaling. Results are reported as the mean of 
triplicate determinations ± SD. Each graph is representative of three independent 
experiments. (B) Immortalized WT, Mal-deficient and Mal-deficient macrophages 
expressing D96N were stimulated for 2 hours with LPS (100 ng/ml). Total RNA was 
extracted. Levels of mRNA for IFN-β were determined by Q-PCR and normalized to 
hypoxanthine phosphoribosyltransferase 1 (HPRT1) level of expression. Results are 
reported as the mean of duplicate determinations ± SD. This graph is representative of two independent experiments. 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FIGURE II.6: Cells expressing D96N have impaired cytokine production 
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using Real-Time PCR (FIG II.6B). D96N expressing macrophages induced comparable 
amounts of IFN-β mRNA as WT and Mal deficient cells. Thus, macrophages expressing 
the D96N variant of Mal are defective in signaling through TLR2 and the MyD88 branch 
of TLR4, while signaling initiated through other TLRs occurs normally. 
IκB degradation assays: NF- κB is the predominant transcription factor responsible for 
pro-inflammatory cytokine production downstream of TLR2 and MyD88-dependent 
TLR4 signaling pathways.  We therefore examined the activation of NF-κB (via IκB 
degradation) after LPS and PAM2CSK4 treatment in the reconstituted cell lines mentioned 
above. In Mal-deficient macrophages, IκB degradation is abrogated upon PAM2CSK4 
treatment, whereas, for LPS stimulation, Mal-deficient macrophages undergo delayed 
degradation (237). In WT BMDMs, IκB was completely degraded at 10 min after LPS or 
PAM2CSK4 treatment (FIG II.7, row A). As expected, Mal-deficient BMDMs had a 
delayed degradation profile in the case of LPS (FIG II.7, left panel, row B) and exhibited 
no degradation in the case of PAM2CSK4 treatment (FIG II.7, right panel, row B). 
Immortalized wild type and Mal-deficient cell lines mimicked their primary cell types 
(FIG II.7, rows C, D). Mal-deficient cell lines expressing wild type Mal, A9P, R13W, 
S180L or V197I degraded IκB at 10 minutes, like the wild type immortalized cells (FIG 
II.7, rows E-G, I, J).  In contrast however, and in agreement with the cytokine data, cells 
expressing the D96N mutant behaved like the Mal-deficient cells (FIG II.7, row H), with 
no degradation in the case of PAM2CSK4 and a delayed degradation profile following 
LPS treatment. Thus, Mal D96N is a hypomorphic, if not a null variant of Mal, fully 
defective in NF-κB activation. 
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 FIGURE II.7:  Mal D96N fails to degrade IκB-α  effectively 
 
 
 
 
FIGURE II.7:  Mal D96N fails to degrade IκB-α  effectively.  NF- κB activation in the 
reconstituted cell lines was examined via IκB-α degradation assay. The cells were 
stimulated with LPS (left panel) or PAM2CSK4  (right panel) for the indicated time points 
and the whole cell lysates loaded on a denaturing gel, transferred to nitrocellulose 
membrane and blotted with IκB-α antibody.  Levels of GAPDH act as an internal loading 
control. 
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Interaction studies with TLR4, TLR2 and MyD88: Having established the failure of Mal 
D96N to signal, we next sought an explanation for the inability of D96N to transduce the 
signal downstream of TLR2 and TLR4.  It is thought that Mal acts as a bridging adapter 
between the receptor (TLR2 or TLR4) and MyD88, and thus physically interacts with 
both (238). We therefore examined whether the D96N mutation affected the ability of 
Mal to interact with TLR2, TLR4 or MyD88. Transient transfections in HEK293T cells, 
followed by immunoprecipitation assays were carried out to address this question (FIG 
II.8). As expected, wild type Mal interacted with the receptors TLR2 (FIG II.8A) and 
TLR4 (FIG II.8B) and with MyD88 (FIG II.8C, lane 6). Like wild type Mal, D96N could 
be co-immunoprecipitated with both TLR2 and TLR4, indicating that this mutation does 
not affect the ability of Mal to interact with either of these receptors. However, D96N 
was severely compromised in its ability to interact with MyD88. While wild type Mal 
could co-immunoprecipitate with MyD88, D96N could not  (FIG II.8C, lane 7). Thus, the 
loss-of-function phenotype of D96N appeared to result from its inability to interact with 
MyD88. 
Modeling studies for Mal suggest that a change in surface charge accounts for the D96N 
phenotype: We generated high quality models of the TIR domains of both WT and D96N 
Mal, using the resolved crystal structures of TLR1 and 2 as templates (111). The Mal TIR 
domain was predicted to have good geometry, with none of its phi-psi dihedral angles 
within disallowed regions of a Ramachandran plot, and 90.6% in geometrically favored 
regions.  JOY and Verify3D outputs (232) revealed that the environment of residues in 
the model of Mal are similar to those of the TLR1 and TLR2 TIR domains used as 
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FIGURE II.8: D96N fails to interact with MyD88.  HEK293T cells were plated to half 
confluence in 6 well plates.  After attachment, cells were transiently transfected with 
either TLR2-YFP (A), TLR4-CFP (B) or MyD88-CFP (C) and FLAG tagged Mal WT or 
Mal D96N.  Two days after transfection, supernatants were removed, and cells were 
lysed. Anti-GFP polyclonal antibody was used for immunoprecipitation (IP). 
Immunoprecipitates were loaded on a denaturing gel, transferred to nitrocellulose 
membrane, and visualized with a monoclonal anti-FLAG-HRP antibody. The 
immunoprecipitation of TLR2-YFP, TLR4-CFP and MyD88-CFP was confirmed by 
immunoblotting the membrane with anti-GFP antibody. The same antibodies were used 
to check the level of expression of the proteins in whole cell lysates. IB: immunoblot 
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FIGURE II.8: D96N fails to interact with MyD88 
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templates, and were not energetically unfavorable. Residue D96 was predicted to lie on 
the surface of the TIR domain in a highly negatively charged region.   
Mal D96N was modeled using the same approach as the wild-type protein, and 
exhibited no significant changes in structure or geometry compared to wild-type Mal, as 
might have been expected from a change in a surface residue. This prediction was further 
supported using software capable of estimating the level of structural destabilization 
encoded by point mutations (SDM) (233). This program uses a statistical potential energy 
function that predicts the effect that a specific amino-acid substitution may have on the 
stability of that protein and produces the pseudo free energy difference between a wild-
type and mutant protein (233, 239). The D96N substitution was shown to induce 
structural alterations with corresponding pseudo ∆∆G values of 0.729 kcal/mol, implying 
that there is no significant change to the overall stability of the Mal TIR domain caused 
by this mutation.   
The loss of a surface-exposed negatively charged side-chain resulting from an 
aspartic acid to asparagine substitution (D->N) (FIG II.9A) would be predicted to be 
responsible for the experimentally observed disruption of the Mal/MyD88 protein 
interaction. FIG II.9B shows a model of the TLR4- TIR homodimer (cyan) /Mal TIR 
domain  (magenta) complex. The change in electrostatic charge resides near a surface 
region (Pattern 108-122; shown in yellow) that is predicted to interact with MyD88 [(FIG 
II.9B) and (232)]. Moreover, residue 96 lies distal to the BB loop region of Mal (92) that 
has previously been proposed to interact with TLR4  [(FIG II.9B) and (232)], consistent  
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FIGURE II.9.  The D96N mutation results in a loss of negative charge on the surface 
of the Mal-TIR domain in a region predicted to be involved in MyD88, but not TLR 
interactions. (A) Comparison of the electrostatic surfaces of wild-type (left) and N96 
(right) Mal-TIR models indicating a loss of negative charge in the region of residue 96 
(circled). (B) Model of the TLR4-TIR homodimer (cyan) /Mal TIR domain  (magenta) 
complex indicating the location of Mal-D96 (red, spacefill), its proximity to the predicted 
MyD88 interaction surface (pattern 108-122, yellow) and its distance from the BB-loop 
region that is vital for Mal’s interaction with TLR4 (cyan). 
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FIGURE II.9:  The D96N mutation results in a loss of negative charge on the surface 
of the Mal-TIR domain in a region predicted to be involved in MyD88, but not TLR 
interactions. 
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with the immunoprecipitation studies in FIG II.8 indicating that Mal D96N retains its 
ability to bind to TLRs 2 and 4 even though it is no longer capable of binding MyD88. 
Mal D96N fails to recruit MyD88 to the cell membrane: MyD88 is recruited to the cell 
membrane via TIR-TIR interactions with Mal. Exogenous MyD88 when expressed in 
cells, is present in condensed aggregates in the cytoplasm. Co-expression of Mal (wt) 
however, leads to expression of MyD88 at the cell membrane where it colocalizes with 
Mal (139). We expressed citrine-tagged MyD88 either by itself or in conjunction with 
FLAG-tagged wt Mal or Mal D96N in HEK293T cells. As expected, MyD88 when 
expressed by itself, could be seen as aggregate structures in the cell (FIG II.10, 
uppermost panel). Co-expression with wt Mal, led to the expression of MyD88 at the cell 
membrane (FIG II.10, middle panel). However, when we expressed MyD88 with Mal 
D96N, MyD88 retained its aggregate form and was not recruited to the cell membrane 
(FIG II.10, bottom panel). This is in accordance with our interaction data since Mal 
D96N is unable to interact with MyD88 and therefore fails to recruit MyD88 to the cell 
membrane.  
Murine Mal D96N is able to drive NF-κB reporter: Murine Mal has an additional 20 
amino acids at the N-terminus as compared to Human Mal. The 96th residue in human 
Mal is thus at position 116th in murine Mal. However, aspartic acid is conserved at this 
position in both human and murine Mal. We tested the activity of Mal D116N in NF-κB 
reporter assay. Like human Mal, murine wild-type Mal was able to drive NF-κB reporter 
(FIG II.11). However, unexpectedly, Mal D116N was also sufficient in its ability to drive 
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FIGURE II.10. Mal D96N fails to recruit MyD88 to the cell membrane 
 
 
 
 
 
 
 
 
 
 
 
FIGURE II.10: Mal D96N fails to recruit MyD88 to the cell membrane: HEK293T 
cells were plated in glass-bottom confocal dishes at a density of 250,000 cells per dish. 
Next day, the cells were transfected with either MyD88 by itself or in conjunction with 
wt Mal or Mal D96N. The cells were imaged using standard confocal procedures. 
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FIGURE II.11: Murine Mal D96N is able to drive NF-κB reporter activity 
 
 
 
 
 
 
 
 
 FIGURE II.11: Murine Mal D96N is able to drive NF-κB reporter activity: 
HEK293T cells were transfected with FLAG tagged versions of the indicated Mal 
constructs along with NF-κB-luciferase. Twenty-four hours later, luciferase activity was 
measured in cell lysates. Renilla-luciferase values were used to normalize for transfection 
efficiency. Results are reported as a mean of triplicate determinations ± S.D. The graphs 
are a representative of at-least two independent experiments. 
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the reporter. Thus, unlike human Mal D96N, murine Mal D116N is capable of activating 
NF-κB. This difference in the signaling capabilities between human and murine D96N 
(or D116N) might be due to the additional 20 amino acids at the N-terminus of murine 
Mal, which may change the conformation of the protein. 
Genotyping of TIRAP in human populations:  Mal D96N is an inactivating mutation, 
which is unable to transduce signaling downstream of TLR2 and TLR4. We next 
addressed the question of what the frequency of this polymorphism was in the general 
population. We sequenced TIRAP in African Tanzanian (n=91), Chinese Han (n=97) and 
Caucasian Dutch (n=188) individuals. The African Tanzanian and the Chinese 
individuals all apparently expressed wild-type Mal. However, one individual in the 
Caucasian Dutch cohort was heterozygous for the D96N mutation (TABLE II.1). 
Although this experiment is not an exhaustive assessment of the frequency of Mal D96N 
in all populations, we can conclude that this variation of Mal has a very low prevalence in 
the populations studied. This is understandable, given the strong phenotype in innate 
signaling that we observed in our experiments.  Indeed, individuals homozygous for 
MalD96N would be expected to have a phenotype similar to what has been reported for 
MyD88 deficiency, i.e., hypersusceptible to common life-threatening pathogens such as 
S. pneumoniae (240). 
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TABLE II.1: Genotyping of Mal in three different populations 
 
 
population N 96th residue 
African Tanzanian 91 All D/D 
Chinese Han 97 All D/D 
Caucasian Dutch  188 187:D/D;  1:D/N 
 
 
TABLE II.1 Genotyping of Mal:  Genomic DNA from 91 African Tanzanians, 97 
Chinese Han and 188 Caucasian Dutch individuals was screened for the presence of 
TIRAP D96N (which encodes for Mal D96N).   
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Discussion 
TLRs are the key sensors of microbial infection in mammals. Upon encountering 
a pathogen, they elicit an inflammatory response involving an intricate network of 
signaling molecules. Changes in the structure of the TLR signaling components can have 
dramatic effects on the outcome of various infectious diseases. Some of these changes 
may be caused by the presence of a SNP in the coding region of the protein.  The effects 
of SNPs on the structure of proteins and the consequent effect on TLR signaling have 
been described in many studies (241-244).  
TIR domain interactions between the TLR components are a necessary event for 
downstream signaling to occur. SNPs in adapter proteins could thus be influential in 
determining the progression of infection. Incidentally, Mal is the most polymorphic of all 
the adapter proteins. Of the eight known coding polymorphisms in Mal, only one, S180L, 
has been previously described (224). Khor et al. found that the heterozygotes carrying 
this polymorphism were protected from malaria, tuberculosis and bacteremia. In view of 
these observations we hypothesized that SNPs in Mal could affect TLR2 and TLR4 
signaling.  
The data presented herein makes a strong case that a variant of Mal, D96N, is 
essentially non-functional. Our model would indicate that Mal D96N does not bind 
MyD88 due to a critically located change in charge on its surface, and hence fails to 
function as a bridging adapter between the receptors TLR2 and TLR4 and the sorting 
adapter MyD88. Its inability to engage MyD88 prevents activation of NF-kB, IRF-5 and 
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most likely AP-1, all of which are required to trigger pro-inflammatory cytokine 
production.    
A noteworthy point is that Mal-deficient macrophages from mice were all 
reconstituted with human Mal. The TIR domains of murine and human Mal are 71% 
identical and indeed, human Mal was capable of fully restoring function in these cells. As 
expected, D96N was defective in pro-inflammatory cytokine production upon 
stimulation. A surprising finding was the absence of a phenotype for Mal S180L in our 
studies, an outcome that conceivably could be due to difference in species of the 
reconstituted protein and cell types, although this explanation would not hold for the 
ability of transfected Mal S180L to drive reporter constructs in HEK293T cells. In our 
experiments Mal S180L was fully active and its effect upon stimulation comparable to 
that of wild-type Mal. It is true that we have no truly satisfactory explanation for the 
discrepancy between our findings and that of Khor et al (224).   One explanation for our 
findings, at least in Mal knockout macrophages complemented with the various mutant 
Mal constructs, is that Mal S180L may be a hypomorphic lesion, rather than a null 
mutation.  Hence, sufficient overexpression may overcome its relative inability to signal. 
Indeed, Western Blots of the transduced Mal, as well as the variants, using an established 
anti-Mal Ab, suggested that the recombinant proteins were at least 10-100 fold more 
abundant in the immortalized cell lines than endogenous wild-type Mal (data not shown). 
Clearly, this discrepancy from previously published results need to be better analysed. To 
this effect, a knock-in mouse expressing the S180L lesion has been engineered (data not 
shown), and will need to be characterized to determine the nature of this mutation in vivo.   
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Residue 96 and the surrounding 10-12 amino acid region is fairly well conserved 
in the known orthologs of TIRAP.  The presence of an aspartic acid (D) at position 96 
creates a negatively charged surface that is conducive to protein-protein interactions. 
Conversion to uncharged asparagine would thus be expected to change the binding 
potential of the protein. Modeling of the TIR domains of Mal and Mal D96N suggested 
that the residue 96 lies away from the TLR4 or TLR2 binding site but is in very close 
proximity to the MyD88 binding site (Fig 5). These predictions were confirmed in co-
immunoprecipitation assays and show that Mal D96N retains the ability to bind TLR2 
and TL4 but is unable to bind MyD88. Hence, this characterization of a natural Mal 
mutant identifies, with apparent pinpoint precision, a single residue in the TIR domain of 
Mal that is critical for its interaction with MyD88.  
The frequency of D96N in the populations we analyzed was very low. In the 
initial screen, we genotyped individuals from three different populations. However, we 
found just one individual (out of 376) who was heterozygous for D96N. Considering the 
deleterious phenotype we observe, the low frequency of this polymorphism is not 
unexpected. As the mutation exists, it is nearly certain that there are sporadic individuals 
born who are homozygous for D96N. Since the data suggest the failure to bind MyD88 is 
the reason for the phenotype of D96N, we believe that individuals carrying this mutation 
in a homozygous state would be extremely susceptible to both gram-negative and gram-
positive infections. In view of the reported serious clinical significance of MyD88 and 
IRAK4 deficiencies, two gene products that are downstream of Mal and which should be 
similar to Mal D96N expression, we believe that Mal D96N represents a rare, potentially 
79 
life-threatening mutation.(216, 217) Indeed, individuals occasionally present for medical 
case with sepsis in the absence of any known risk factors; we would suggest that Mal 
D96N should be considered under such circumstances as a potential cause of such a 
clinical presentation.  
In contrast to what one might expect for the rare individual with two mutant 
alleles, the fact that this amino acid variant exists in the population, albeit at a very low 
frequency, suggests that heterozygous individuals have a survival advantage under some, 
but still undefined, circumstances.  The key to determining the nature of this hypothetical 
heterozygous advantage is to analyze enough individuals from enough different 
populations to define clinical correlates.   
 
 
    
80 
 
                                     PREFACE TO CHAPTER III 
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A NATURAL LOSS-OF-FUNCTION MUTATION OF MYD88 
DISRUPTS ITS ABILITY TO FORM MYDDOSOMES 
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Abstract 
Myeloid differentiation protein 88 (MyD88) is a key signaling adapter in Toll-like 
receptor (TLR) signaling. MyD88 is also one of the most polymorphic adapter proteins.  
We screened the reported non-synonymous coding mutations in MyD88 to identify 
variants with altered function. In reporter assays, a death domain variant, S34Y, was 
found to be inactive. Importantly, in reconstituted macrophage-like cell lines derived 
from knockout mice, MyD88 S34Y was severely compromised in its ability to respond to 
all MyD88-dependent TLR ligands. Unlike wild type MyD88, S34Y is unable to form 
distinct foci in the cells but is present diffused in the cytoplasm.  We observed that 
IRAK4 colocalizes with MyD88 in these aggregates and thus these foci appear to be 
“Myddosomes”. The MyD88 S34Y loss of function mutant demonstrates how proper 
cellular localization of MyD88 to the Myddosome is a feature required for MyD88 
function.  
 
 
 
 
 
 
83 
 
Introduction 
TLRs are a part of the innate immune system and play a critical role in host 
defense against a variety of pathogens. Ten functional TLRs in humans and 12 in mice 
have been identified to date (245). Each TLR recognizes different categories of 
evolutionarily conserved patterns called pathogen associated molecular patterns (PAMPs) 
in microbes. For example, TLR4 recognizes lipopolysaccharide (LPS) from the cell walls 
of bacteria while CpG-rich DNA from bacteria and viruses acts as the ligand for TLR9.  
Much of the diversity of TLR pathways can be attributed to differential use of the 
TIR domain containing adapter proteins. There are 4 adapter proteins: MyD88, MyD88 
adapter-like (Mal), also called TIR domain containing adapter protein (TIRAP), TIR-
domain-containing adapter-inducing interferon-β (TRIF) and TRIF-related adaptor 
molecule (TRAM). MyD88 is a key adapter protein involved in signaling from all of the 
TLRs except TLR3 and the TRIF mediated arm of TLR4 signaling.  Thus, depending on 
its use, TLR pathways can be divided into MyD88-dependent and MyD88-independent 
pathways. The engagement of a particular TLR by its ligand triggers a signaling cascade, 
which culminates in the secretion of various pro-inflammatory cytokines and interferons.  
MyD88 is a 296 amino acid protein with a modular domain structure. In addition 
to the N-terminal TIR domain, it has a death domain at its C-terminus. The crystal 
structure of the MyD88 death domain has recently been resolved and it reveals that 
MyD88 exists in oligomeric form in solution (246).  These oligomers of MyD88 can 
recruit the death domains of IRAK4 and IRAK2 to form a ternary complex called the 
Myddosome.   
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The importance of single nucleotide polymorphisms (SNPs) in TLR-related 
proteins has recently been brought to the forefront, with many studies implicating SNPs 
in disease susceptibility and outcome (247-251). Mal and MyD88 are the most 
polymorphic of the four adapter proteins and Mal has received the most scrutiny in this 
regard (222, 224, 252). However, other than a study by Von Bernuth et al., where 
children with MyD88 deficiencies were shown to have recurrent pyogenic bacterial 
infections (240), studies on MyD88 variants have been scarce.  The central role of 
MyD88 in TLR signaling thus warrants a deeper understanding of the effects of SNPs on 
the activity/function of MyD88.  
In this study we have screened the 6 non-synonymous polymorphisms (FIG III.1) 
in the coding region of MyD88 with the aim of identifying polymorphisms that alter the 
function of MyD88. We identify and characterize a death domain variant, S34Y that is 
completely inactive in all MyD88-dependent TLR signaling.  We further show that this 
mutant has a localization pattern different from that of wild type MyD88 and is unable to 
form Myddosomes with IRAK4 and IRAK2. 
 
Förster (or fluorescence) resonance energy transfer (FRET) 
This chapter employs the technique of FRET rather extensively. Here, I have 
explained the basic concepts of this technique. 
FRET is a valuable tool to detect dynamic molecular interactions between two 
fluorescently tagged proteins. Traditionally, imaging techniques rely on co-localization of 
proteins to demonstrate interactions. If two proteins are co-localized, this indicates that  
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FIGURE III.1: A schematic showing the positions of coding SNPs in MyD88 
 
 
 
 
 
 
 
 
 
 
 
FIGURE III.1: A schematic showing the location of non-synonymous coding 
polymorphisms in MyD88. There are 6 SNPs in the coding region of human MyD88 
(depicted here by arrows). DD (death domain) ; TIR (Toll/interleukin-1 receptor domain)  
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their spatial proximity is beyond optical resolution (i.e., 100 nm lateral). It does not 
however have any bearing on the interaction between the two participating proteins. 
FRET can detect and quantitate interactions between two fluorescently tagged proteins. 
FRET occurs between two fluorophores: donor and acceptor. A prerequisite for FRET to 
occur, is that the donor emission spectra must overlap with the excitation spectra of the 
acceptor. When the two fluorphores are more than 10 nm apart, excitation of the donor 
leads to the characteristic donor emission. If however the donor and the acceptor are 
within 10 nm of each other, some of the energy from the donor emission is transferred to 
the acceptor fluorophore and because of the spectral overlap this energy is able to excite 
the acceptor leading to emission at the acceptor’s emission wavelength. Thus if two 
proteins tagged with FRET compatible fluorophores interact, an emission at the 
acceptor’s emission wavelength can be observed upon excitation at the donor’s 
absorption wavelength (FIG III.2). 
 Sensitized emission  (SE) is one of the most used methods for evaluation of FRET 
efficiencies. This method requires reference samples (donor only as well as acceptor 
only) in addition to the FRET or the experimental specimen. For each sample, the donor 
and the FRET signal (donor excitation only) is measured in sequence with the detection 
of the acceptor (acceptor excitation only).  The reference samples are used to obtain 
calibration coefficients to correct for excitation and emission cross talk. 
 
The equation used to calculate FRET efficiency is: 
         EA = B – A * b – C * c 
                            C 
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A, B, C correspond to the intensities of the 3 signals (donor, FRET, acceptor) and b & c 
are calibration coefficients calculated from the reference samples. 
b = donor emission + crosstalk ratio  
c = acceptor excitation crosstalk ratio 
 
 
FRET efficiency is inversely proportional to the distance separating the FRET pair. 
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FIGURE III.2: Schematic representation of FRET (Förster resonance energy 
transfer). A typical spectral graph depicting overlap between the donor emission and the 
acceptor excitation spectra. The lower panels define the criteria for FRET to occur 
between two fluorophores. 
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FIGURE III.2: Schematic representation of FRET  
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Experimental procedures 
Plasmids and site directed mutagenesis: The plasmids pEFBOS-MyD88-HA (253), 
pCMV-IRF5-FLAG (226), NF-κB-luciferase, ISRE-luciferase, and Renilla-luciferase 
(158); and the retroviral vector pMSCV2.2-IRES-GFP (227) have been described 
elsewhere. The different variants of MyD88 (in pEFBOS-MyD88-HA and pMSCV2.2-
ISRE-GFP background) were generated by using the QuickChange site directed 
mutagenesis kit (Stratagene) according to the manufacturer’s instructions. Cerulean-
tagged IRAK-4 and citrine-tagged MyD88 were cloned into a vector that was modified 
from the original pCLXSN backbone from Imgenex (254). It has been named pRP by us. 
Subcloning was carried out using unique restriction sites in the multiple cloning site  
(MCS). All of the expression constructs were verified by sequencing. 
Luciferase Reporter Assay: HEK293T cells were seeded in a 96 well plate at a density of 
20,000 cells/well and transfected the next day with either NF-κB or interferon stimulated 
response element (ISRE) luciferase reporter (40 ng), renilla reporter (40 ng) and the 
indicated amounts of either pEFBOS-MyD88 (WT) or the different variants using 
Genejuice (EMD Biosciences, San Diego, USA). In the case of the ISRE reporter assay, 
IRF5 (5 ng) was cotransfected.  Twenty-four hours post transfection, reporter gene 
activity was measured using the Dual Luciferase Assay System (Promega). The 
thymidine-kinase Renilla luciferase reporter values were used to normalize the data for 
transfection efficiency. 
Retroviral Transduction of Immortalized Macrophage-like Cell Lines: The immortalized 
MyD88 deficient macrophage-like cell line has been described elsewhere (255). The  
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retroviral vector MSCV2.2 (227) carrying either FLAG tagged WT MyD88 or MyD88 
S34Y was used to transduce MyD88-deficient cells. This retrovirus transcribes GFP from 
an internal ribosomal entry sequence (IRES) element. The positive cells were thus sorted 
based on GFP expression and the expression of the MyD88 proteins was compared by 
immunoblotting with anti-FLAG antibody. 
Enzyme-linked Immunosorbent Assay: Wild type, MyD88-deficient and MyD88-deficient 
cells expressing WT MyD88 or MyD88 S34Y were seeded into 96-well plates at a 
density of 25,000 cells per well and stimulated overnight with TLR ligands at the 
indicated concentrations.  TNF-α in the supernatants was measured using ELISA kits 
from R&D Systems as per the manufacturer’s instructions.  The same supernatants were 
also assessed for IFN-β levels as described (256). 
IκB-α degradation and MAPK activation assays: Wild type, MyD88-deficient and 
MyD88-deficient cells expressing WT MyD88 or MyD88 S34Y were seeded into a 6-
well plate at a density of 2X106 cells per well. The next day, the cells were stimulated 
with either PAM2CSK4 (10nM) or R848 (20µM) for the indicated time intervals. Cell 
lysates were run on an SDS denaturing gel, transferred to a nitrocellulose membrane and 
immunoblotted with either anti-IκB-α antibody or anti-phospho-p38 antibody (Cell 
Signaling Technology, MA, USA). Anti-glyceride-3 phosphate dehydrogenase (GAPDH) 
(Advanced Immunochemicals) or anti-total p38 antibodies respectively were used to 
reprobe the membranes to check for equal loading of the gels. 
IRAK-1 degradation assays: Cells were plated in a 6-well plate at a density of 2X106 
cells per well and stimulated the next day with either PAM2CSK4 (10nM) or R848 
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(20µM) for the indicated time intervals. Cell lysates were run on a denaturing gel and 
western blotted with anti-IRAK1 antibody (Cell Signaling Technology). GAPDH was 
used as an internal loading control. 
Confocal Microscopy Imaging:  HEK293T cells were seeded in 35-mm glass bottom 
tissue culture dishes (Mat Tek Corporation, MA, USA) at a density of 250,000 cells per 
dish. Next day, the cells were transiently transfected with the indicated plasmids. 
Twenty-four hours later, live cells were imaged on a Leica SP2 AOBS confocal laser-
scanning microscope. A sequential scan was conducted for co-localization studies to rule 
out any possibility of cross talk between the different fluorophores.  
Immunoprecipitations and immunoblots: HEK293T cells were transfected with MyD88-
HA/S34Y-HA and either IRAK4-FLAG, IRAKI-FLAG or TRAF6-FLAG. Two days 
post-transfection, cells were harvested and the lysates were incubated overnight with 
polyclonal anti-HA antibody (SIGMA, MO, USA) and Poly-A Sepharose beads. Rabbit 
IgG was used as a control. The processed samples were run on an SDS gel, transferred to 
nitrocellulose membrane and probed with an HRP conjugated anti-FLAG antibody 
(SIGMA, MO, USA).  The immunoprecipitation of MyD88-HA or S34Y -HA was 
checked by immunoblotting the same membrane with monoclonal HA antibody 
conjugated with HRP (SIGMA, MO, USA). Expression level of the proteins in whole cell 
lysates was checked by immunoblotting with HRP conjugated anti-FLAG antibody and 
HRP-conjugated anti-HA antibody. 
Recruitment of MyD88 to the cell membrane: MyD88-deficient macrophage-like cell line 
was infected with retrovirus carrying either MyD88(WT)-citrine or S34Y-citrine. The 
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positive cells were sorted by flow cytometry and then allowed to recover for 2-3 days. 
The cells were seeded in 35-mm glass bottom tissue culture dishes at a density of 250,000 
cells per dish. Next day, they were stimulated with either LPS (100 ng/ml) or poly I:C (20 
µg/ml). 
Fluorescence Resonance Energy Transfer (FRET):  HEK293T cells were seeded in 35-
mm glass bottom tissue culture dishes (Mat Tek Corporation, MA, USA) at a density of 
150,000 cells per dish. Next day, the cells were transiently transfected with the indicated 
plasmids. FRET between the respective proteins was calculated by measuring sensitized 
emission (SE) fluorescence using the FRET SE wizard on the Leica SP2 confocal laser-
scanning microscope. In each case, cerulean-tagged protein acted as the donor 
fluorophore while the citrine-tagged protein functioned as the acceptor fluorophore. 
Excitation wavelengths for the donor and acceptor were 405 nM and 514 nM 
respectively. The FRET efficiency is shown as a color-coded scale of values between 0 to 
100%. The average of three selected regions of interest (ROIs) was used to quantitate the 
FRET efficiency for each sample. 
 
Results 
S34Y over-expression fails to activate both NF-κB and IRF5-dependent ISRE reporters: 
Human MyD88 has six non-synonymous single nucleotide polymorphisms (SNPs) in its 
coding region (FIG III.1). When expressed in HEK293T cells, all mutants are expressed 
at levels similar to wild type MyD88 (FIG III.3A), indicating no intrinsic protein stability 
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FIGURE III.3: MyD88 S34Y is unable to activate NF-κB and IRF-5 dependent 
ISRE reporters: (A) HEK293T cells were transfected with HA tagged versions of either 
wild type MyD88 or the different variants of MyD88 and expression levels were checked 
using anti-HA antibody. (B) HEK293T cells were transfected with the indicated MyD88 
construct and either NF-κB-luciferase (left panel) or ISRE-luciferase + IRF5 (right 
panel). 24 hours later, luciferase activity was measured in cell lysates. Renilla-luciferase 
values were used to normalize for transfection efficiency. Results are reported as a mean 
of triplicate determinations ± S.D. The graphs are a representative of at-least two 
independent experiments.  
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FIGURE III.3: MyD88 S34Y is unable to activate NF-κB and IRF-5 dependent 
ISRE reporters: 
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defect. To identify variants with altered function, we initially screened all the known 
SNPs in NF-κB reporter assays in HEK293T cells. Wild type MyD88, when 
overexpressed, can drive NF-κB reporter by itself. As evident in FIG III.3B (left panel), 
most MyD88 variants exhibited comparable (L35V, L74M, K115N, V178I) or slightly 
reduced (R98C) activity to wild type MyD88. One of the variants, S34Y, however, was 
completely inactive in driving the NF-κB reporter. Additionally, we tested the activity of 
the MyD88 variants in IRF5-mediated ISRE luciferase reporter assays. Interferon 
response factor 5 (IRF5) is a transcription factor whose activation is dependent on 
MyD88. Similar to the NF-κB luciferase assay, wild type MyD88 and all the variants 
except for S34Y were able to activate the ISRE reporter (FIG III.3B, right panel). S34Y 
was completely compromised in its ability to drive the ISRE luciferase reporter.  
S34Y is unable to restore function in immortalized MyD88-deficient macrophage like cell 
line: To study these polymorphisms in a MyD88 deficient background, we transduced 
immortalized MyD88-deficient macrophage cell line (255) with a retrovirus MSCV2.2 
(227) carrying an HA-tagged version of either wild type MyD88 or S34Y. This retrovirus 
transcribes GFP from an IRES element, thus making the positively transduced cells 
fluorescent. Western blotting with an anti-HA antibody confirmed comparable levels of 
expression of wild type MyD88 and S34Y (FIG III.4A). When stimulated with the 
different TLR ligands, immortalized wild type cells responded to all the tested ligands 
(FIG III.4B) and secreted appreciable amounts of the cytokine TNF-α. On the other hand, 
MyD88 knockout cells could not mount a response to any ligand (LPS, PAM2CSK4, 
CPG, R848) except poly I:C, which is a TLR3 ligand and signals independently of 
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FIGURE III.4: MyD88 deficient macrophages expressing S34Y have impaired 
cytokine production: (A) MyD88 deficient macrophages were infected with an IRES-
GFP expressing retrovirus MSCV2.2, carrying HA tagged versions of either wild type 
MyD88 or the mutant S34Y. The positive cells were sorted based on GFP expression and 
the expression levels of the proteins were checked using an anti-HA antibody. (B) The 
cells were stimulated overnight with the indicated TLR ligands and the levels of TNF-α 
in the culture supernatants were analyzed by ELISA. Results are reported as a mean of 
triplicate determinations ± S.D. The graph is a representative of three independent 
experiments. (C) The same supernatants (only LPS stimulation) were analyzed for IFN-β 
levels by ELISA. Results are reported as a mean of triplicate determinations ± S.D. The 
graph is a representative of three independent experiments. 
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FIGURE III.4: MyD88 deficient macrophages expressing S34Y have impaired 
cytokine production but IFN-β  production by the MyD88-independent pathway is 
intact. 
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MyD88. As expected, MyD88 knockout cells expressing wild-type MyD88 behaved just 
like the wild-type cell line and responded to all the ligands (FIG III.4B). In contrast, 
cytokine production in cells expressing S34Y was completely ablated when stimulated 
with any of the MyD88 dependent ligands. They could, however respond just as well as 
the other cell lines to the TLR3 ligand poly I:C. A similar pattern was seen in the case of 
another pro-inflammatory cytokine, IL-6 (data not shown).  To test whether MyD88-
independent pathways are functional in S34Y expressing cells, we measured IFN-β 
production upon LPS stimulation, which is primarily mediated by the adapter TRIF. The 
cells expressing the mutant S34Y were able to produce IFN-β at levels similar to wild 
type cells (FIG III.4 C). Hence, S34Y impairs only MyD88-dependent TLR signaling, 
while cytokine production by MyD88-independent pathways remains unaffected. 
Murine MyD88 S34Y is also a loss-of-function mutation: Serine at residue 34 is 
conserved between mouse and human MyD88. We thus wanted to test whether the same 
mutation in murine MyD88 affects MyD88 signaling. Like human MyD88, wild-type 
murine MyD88 can also activate NF-κB reporter when exogenously expressed in 
HEK293T cells. However, murine S34Y was unable to drive the NF-κB reporter (FIG 
III.5 A).  
 We also generated immortalized MyD88-deficient macrophage-like cell lines 
expressing either wild-type murine MyD88 or murine S34Y. These cell lines were then 
tested for their ability to produce pro-inflammatory cytokines in response to various TLR 
ligands. MyD88-deficient cells expressing wild-type murine MyD88 behaved like the 
wild-type immortalized cells and responded to all the tested ligands. Cells expressing 
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FIGURE III.5: Murine MyD88 S34Y is a loss-of-function mutation: (A) HEK293T 
cells were transfected with HA tagged versions of either wild type murine MyD88 or 
murine S34Y along with NF-κB-luciferase. Twenty-four hours later, luciferase activity 
was measured in cell lysates. Renilla-luciferase values were used to normalize for 
transfection efficiency. Results are reported as a mean of triplicate determinations ± S.D. 
The graphs are a representative of at-least two independent experiments. (B) MyD88 
deficient macrophages were infected with an IRES-GFP expressing retrovirus MSCV2.2, 
carrying HA tagged versions of either wild type murine MyD88 or murine S34Y. The 
positive cells were sorted based on GFP expression. The cells were stimulated overnight 
with the indicated TLR ligands and the levels of TNF-α in the culture supernatants were 
analyzed by ELISA. Results are reported as a mean of triplicate determinations ± S.D. 
The graph is a representative of two independent experiments. 
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FIGURE III.5: Murine MyD88 S34Y is a loss-of-function mutation
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murine S34Y however, were unable to respond to any of the MyD88-dependent ligands 
(FIG III.5 B). Nevertheless, they could make TNF-α in response to poly I:C, which is a 
TLR3 ligand. Thus, like human MyD88, the mutation S34Y in mouse MyD88 also 
affects the signaling potential of MyD88. 
NF-κB and MAPK (p38) activation is impaired in macrophages that express 
MyD88 S34Y: TLR engagement leads to the activation of a variety of transcription 
factors like NF-κB, AP-1 and interferon response factors (IRFs) (257), as well as mitogen 
activated protein kinases (MAPKs) (258), though NF-κB is the predominant transcription 
factor involved in MyD88 dependent signaling. IκB-α is the inhibitor of NF-κB and its 
degradation via ubiquitination implies activation of NF-κB. We thus tested the activation 
status of NF-κB in the cell lines expressing wild type human MyD88 or S34Y.  
Immortalized wild type, MyD88-deficient, MyD88-deficient cells expressing wild type 
MyD88 or S34Y were stimulated with either PAM2CSK4 (a TLR2 ligand) or R848 (a 
TLR7 ligand). These two ligands were selected based on the localization pattern of their 
receptors. TLR2 is a cell membrane receptor, while TLR7 is an endosomal TLR. Thus, 
using these ligands gives a complete picture of MyD88 dependent signaling from both 
sites-cell surface as well as the endosome. The immortalized wild type cells responded to 
both PAM2CSK4 and R848 and could degrade IκB-α starting as early as 10 minutes (FIG 
III.6A). MyD88 deficient cells, however, did not respond to either ligand and we could 
see no degradation of IκB-α in these cells. The cells expressing wild type MyD88 
behaved like the wild type macrophages and could degrade IκB-α at 10 minutes. On the 
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FIGURE III.6: IκB degradation and MAPK (p38) activation is impaired in 
macrophages that express MyD88 S34Y: (A) NF-κB activation was examined by 
assessing IκB degradation. Cells were plated in a 6-well plate and stimulated with either 
10nM PAM2CSK4 or 20µM R848 for the indicated time intervals. Cell lysates were 
made, run on a gel, transferred to nitrocellulose membrane and blotted with an anti-IκB 
antibody. GAPDH levels served as an internal loading control. (B) The same cell lysates 
were also analyzed for p38 MAPK activation by examining phosphorylation of p38 using 
anti-pp38 antibody. Total p38 MAPK levels acted as an internal loading control. 
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FIGURE III.6: IκB degradation and MAPK (p38) activation is impaired in 
macrophages that express MyD88 S34Y 
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other hand, the cells expressing S34Y were completely deficient in their ability to 
degrade IκB-α, when stimulated with either PAM2CSK4 or R848 (FIG III.6A).  
Having demonstrated that S34Y expressing cells exhibit impaired NF-κB 
activation, we wondered if this defect in response included impaired MAPK activation. 
We selected p38 MAPK as a prototype of MAPK activation and examined its 
phosphorylation status as a marker for its activation. Phosphorylation of p38 MAPK 
followed the same pattern as NF-κB activation and S34Y expressing cells did not 
phosphorylate p38 upon stimulation with either PAM2CSK4 or R848 (FIG III.6B). Thus, 
S34Y is a non-functional mutation that renders MyD88 completely defective in signaling. 
Signaling through MyD88 S34Y does not lead to the formation of a functional signaling 
complex: Once a TLR is activated by its respective ligand, MyD88 recruits interleukin-1 
receptor associated kinase (IRAK)-1 and IRAK-4 to the receptor complex through death 
domain interactions. IRAK-4 then phosphorylates and activates IRAK-1, which can then 
autophosphorylate itself. This hyperphosphorylated form of IRAK1 then undergoes 
ubiquitination-mediated degradation (170, 259). These phosphorylation and degradation 
events are thus hallmarks of an active signal transduction pathway.  
We initially hypothesized that the S34Y mutant MyD88 is unable to bind either 
IRAK-1 or IRAK-4. However, co-immunoprecipitation assays in HEK293T cells 
revealed that the presence of the S34Y mutation does not affect the ability of MyD88 to 
bind either IRAK-1 or IRAK-4 (FIG III.8). We thius tested whether the activation signal 
is effectively relayed to the downstream effectors by analyzing the degradation of 
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IRAK-1. Treatment with either PAM2CSK4 or R848 results in degradation of IRAK-1 as 
early as 5 minutes, in the wild type immortalized cells (FIG III.7). As expected, the 
MyD88-deficient cells are not able to form an active signalosome and hence cannot 
degrade IRAK-1. MyD88 deficient cells expressing wild type MyD88 behaved similarly 
to wild type cells and could respond to both the tested ligands. The cells expressing 
S34Y, however, were unable to degrade IRAK-1 upon stimulation with PAM2CSK4 or 
R848. Hence, even though MyD88 S34Y is able to interact with IRAK-4 and IRAK-1, 
these interactions are not functional and thus the activation signal is not conveyed to the 
downstream effectors.  
Having shown that MyD88 S34Y is completely defective in signaling through the 
TLRs, we next sought an explanation for this phenotype. We hypothesized that the 
presence of this mutation might affect the interaction of MyD88 with its known binding 
partners. MyD88 is known to bind to the serine-threonine kinases IRAK4 and IRAK1 via 
death domain-death domain interactions. It can also bind to the E3 ubiquitin ligase 
TRAF6. We thus tested the binding of MyD88 S34Y with IRAK4, IRAK1 and TRAF6 
by co-immunoprecipitation assays in HEK293T cells. These studies however, did not 
reveal a defect in the ability of MyD88 S34Y to interact with any of the known binding 
partners of MyD88 (FIG III.8). Like wild-type MyD88, S34Y was able to interact with 
IRAK4, IRAK1 and TRAF6. 
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FIGURE III.7: Macrophages expressing S34Y are unable to degrade IRAK1 
effectively 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE III.7: Macrophages expressing S34Y are unable to degrade IRAK1 
effectively: IRAK1 degradation was examined in the reconstituted cell lines as a marker 
of an active signal complex formation. Cells were plated in a 6-well plate and stimulated 
with either 10nM PAM2CSK4 or 20µM R848 for the indicated time intervals. Cell lysates 
were made, run on a gel, transferred to nitrocellulose membrane and blotted with an anti-
IRAK1 antibody. GAPDH levels served as an internal loading control. 
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FIGURE III.8: MyD88 S34Y retains the ability to bind IRAK4, IRAK1 and TRAF6. 
HEK293T cells were transfected with the indicated plasmids. Two days after 
transfection, supernatants were removed, and cells were lysed. Anti-HA polyclonal 
antibody was used for immunoprecipitation (IP). Immunoprecipitates were loaded on a 
denaturing gel, transferred to nitrocellulose membrane, and visualized with a monoclonal 
anti-FLAG-HRP antibody. The immunoprecipitation of MyD88-HA or S34Y-HA was 
confirmed by immunoblotting the membrane with anti-HA antibody. The same 
antibodies were used to check the level of expression of the proteins in whole cell lysates. 
IB: immunoblot 
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FIGURE III.8:  MyD88 S34Y retains the ability to bind IRAK4, IRAK1 and TRAF6 
(A) IRAK4-MyD88/S34Y interaction (B) IRAK1-MyD88/S34Y interaction 
 
 
 
 
 
 
 
 
 
 
 (C) TRAF6-MyD88/S34Y interaction 
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S34Y has a different localization pattern than wild type MyD88: Since the S34Y mutation 
did not seem to affect any interactions, we next tested whether MyD88 S34Y has a 
different localization pattern than wild type MyD88. In 1998, Jaunin et al. demonstrated 
that wild type MyD88, when expressed in Hela cells, is localized in fibrillar aggregates 
(260). A number of other groups reported similar findings, including our own group (139, 
261). Indeed, we found that when citrine-tagged wild type MyD88 was expressed in 
HEK293T cells, it localized to aggregates or distinct foci in the cytoplasm, with almost 
no diffuse cytoplasmic expression (FIG III.9A, upper panel).  S34Y however, was 
completely diffuse in the cytoplasm, with no aggregate structures (FIG III.9A, lower 
panel). To confirm that the aggregates we see in the case of WT MyD88 are indeed 
oligomeric complexes of MyD88, we carried out FRET analysis with cerulean and 
citrine-tagged MyD88 (WT). Both cerulean and citrine-tagged MyD88 localized to the 
condensed structures in the cell and a very strong FRET signal could be observed 
between the two differentially tagged WT MyD88s (FIG III.9B).  In contrast, cerulean 
and citrine-tagged S34Y co-localized in the cytoplasm with a complete absence of 
aggregates. In this case, the FRET efficiency was significantly lower than the WT 
experimental set, thus demonstrating that the S34Y mutation affects the ability of MyD88 
to form its own oligomeric complexes. 
Some recent studies suggest that the activity/function of MyD88 might be related 
to its correct subcellular targeting or the ability to aggregate in the cytoplasm. A study by 
Nishiya et al. demonstrated that the signaling function of MyD88 is dependent on its 
correct cellular localization and the entire non-TIR region of MyD88 is responsible for its  
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FIGURE III.9: Unlike WT MyD88, S34Y does not form oligomeric aggregates (A) 
Citrine-tagged wild type MyD88 or S34Y were transfected into HEK293T cells. Next 
day, live cells were imaged using standard confocal procedures. CellmaskTM (Invitrogen) 
plasma membrane stain is used to mark the cell membranes (pseudocolored blue). (B) 
HEK293T cells were transiently transfected with the indicated plasmids. FRET between 
cerulean and citrine tagged WT MyD88 or cerulean and citrine tagged S34Y was 
calculated by measuring sensitized emission (SE) fluorescence using FRET SE wizard on 
the Leica SP2 confocal laser-scanning microscope. The FRET efficiency is shown as a 
color-coded scale of values between 0 to 100%.  
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FIGURE III.9: Unlike WT MyD88, S34Y does not form oligomeric aggregates 
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correct localization (262). They further show that the deletions or truncations in this 
region that change the localization of MyD88 making it diffusely expressed in the 
cytoplasm, also render MyD88 inactive in NF-κB reporter assays. Hence, in accordance 
with previously published reports, we show that proper localization of MyD88 is 
indispensible for its function. In addition, we show that a naturally occurring loss-of-
function mutation of MyD88 changes the subcellular localization of MyD88.  
MyD88 S34Y is a dominant negative mutation: Although MyD88 S34Y retains its ability 
to interact with the known binding partners of MyD88, these interactions are not 
functional and the activating signal is not relayed to the downstream effectors. We tested 
whether the expression of S34Y mutant interferes with the function of wild type MyD88 
by sequestering the signaling proteins, thus blocking signal transduction. We co-
transfected increasing amounts of DNA encoding for MyD88 S34Y, keeping the DNA 
amount of wild-type MyD88 constant and assessed NF-κB reporter activity. S34Y mutant 
reduced the ability of wild type MyD88 to drive the reporter in a dose-dependent fashion 
(FIG III.10A). Using retroviral infections we expressed either wild type MyD88 or S34Y 
in wild type immortalized cells. These cells were then tested for their responsiveness to 
various TLR ligands by measuring TNF-α in the supernatants of the stimulated cells. 
Cells expressing wild type MyD88 (in addition to the endogenous MyD88 allele) 
behaved just like the wild type cells and no change could be observed in terms of 
cytokine production (FIG III.10B). However, cells expressing S34Y (in addition to the  
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FIGURE III.10: MyD88 S34Y is a dominant negative mutation: (A) HEK293T cells 
were transfected with the 50 ng of wild type MyD88 construct and the indicated amounts 
of MyD88-S34Y construct, along with NF-κB-luciferase. Twenty-four hours later, 
luciferase activity was measured in cell lysates. Renilla-luciferase values were used to 
normalize for transfection efficiency. Results are reported as a mean of triplicate 
determinations ± S.D. (B) Wild type immortalized macrophages were infected with 
MSCV2.2, carrying HA tagged versions of either wild type MyD88 or the mutant S34Y. 
The positive cells were sorted based on GFP expression. The cells were stimulated 
overnight with the indicated TLR ligands and the levels of TNF-α in the culture 
supernatants were analyzed by ELISA. Results are reported as a mean of triplicate 
determinations ± S.D. (C) HEK293T cells were transfected with MyD88-cerulean or 
S34Y-citrine, either by themselves  (left panel) or co-transfected together (right panel). 
The cells were imaged using standard confocal procedures. 
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FIGURE III.10: MyD88 S34Y is a dominant negative mutation 
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endogenous MyD88 allele) had a phenotype intermediate to wild type and MyD88-
deficient cells. They exhibit significantly reduced cytokine production in response to all 
tested ligands. Thus, we demonstrate by two different assays, that S34Y mutant can 
reduce the signaling activity of wild type MyD88. 
We wondered whether co-expression of S34Y would affect the localization of 
wild type MyD88. MyD88 presents as aggregates in the cytoplasm, whereas S34Y is 
diffuse cytoplasmic. We co-expressed wild type MyD88 tagged with cerulean and S34Y 
tagged with citrine in HEK293T cells. In the presence of S34Y, wild type MyD88 is 
unable to form condensed foci in the cytoplasm. Instead, like the mutant, wild type 
MyD88 is also diffused (FIG III.10C). The ability of MyD88 to form aggregates is linked 
to its function and by disrupting this capacity of MyD88, S34Y renders wild type MyD88 
non-functional. MyD88 S34Y thus acts as a dominant negative mutation. 
S34Y does not traffic to the cell membrane: When citrine-tagged MyD88 (WT) or S34Y 
are expressed in MyD88-deficient macrophages, they both retain their characteristic 
localization pattern. WT MyD88 is present in condensed aggregates whereas S34Y is 
diffused cytoplasmic (FIG III.11A, left panel). To investigate ligand-dependent MyD88 
recruitment to the site of activation, we stimulated the cells with the TLR4 ligand, LPS. 
Forty-five minutes post stimulation, MyD88 could be observed at the cell membrane 
(FIG III.11A, right panel). This mobilization of MyD88 requires activation by a MyD88 
dependent ligand, as poly I:C, a TLR3 ligand, failed to induce mobilization (data not 
shown). However, no change could be observed in S34Y expressing cells. LPS 
stimulation did not lead to S34Y trafficking to the membrane (FIG III.11, right panel). 
117 
 
FIGURE III.11: LPS stimulation of MyD88-deficient macrophages expressing either 
MyD88-citrine or S34Y-citrine. 
 
 
 
 
 
 
 
 
 
 
 
FIGURE III.11: LPS stimulation of MyD88-deficient macrophages expressing either 
MyD88-citrine or S34Y-citrine. Macrophages expressing either citrine-tagged 
MyD88(WT) or S34Y were imaged using standard confocal microscopy. CellmaskTM 
(Invitrogen) plasma membrane stain is used to mark the cell membranes (pseudocolored 
blue). The cells were either left untreated (left panel) or stimulated with LPS (100 ng/ml) 
for 45 minutes (right panel) 
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We also tested the co-localization of MyD88/S34Y with the adapter Mal. When wild-
type MyD88 is co-expressed with Mal/TIRAP, it relocalizes from the condensed foci to 
the cell membrane where it co-localizes with Mal (139). We had similar observations 
when we transiently transfected Mal-cerulean with wild type MyD88-citrine. Instead of 
being localized to distinct foci in the cytoplasm, MyD88 was co-localized at the cell 
membrane with Mal (FIG III.12A). As a control, we co-expressed Mal D96N with wild 
type MyD88. Mal D96N is a naturally occurring mutation of Mal that interferes with 
MyD88 binding (263). As expected, Mal D96N was unable to traffic wild type MyD88 to 
the membrane (chapter II, FIG II.10). In the case of S34Y co-expressed with Mal, S34Y 
retained its diffuse cytoplasmic expression and did not get recruited to the membrane. 
Since co-immunoprecipitation assays did not reveal a defect in the binding of MyD88 
S34Y with Mal, we employed FRET analysis to shed some light on the interactions 
between Mal and MyD88/S34Y. WT MyD88 and Mal co-expression resulted in a strong 
FRET signal limited to the cell membrane, the site of interaction (FIG III.12B). In 
contrast, S34Y and Mal generated a comparatively weaker FRET signal, in the 
cytoplasm. Thus, even though S34Y interacts with Mal in the cytoplasm, it is unable to 
be recruited to the membrane, the functional site for Mal and MyD88 dependent receptor 
activation. The recruitment of wild-type MyD88 but not S34Y to the membrane 
illustrates the fact that the observed aggregates of MyD88 are functional oligomers and 
not merely an artifact of overexpression.  
MyD88 S34Y fails to assemble into Myddosomes: Recently, the crystal structure of the 
MyD88-IRAK4-IRAK1 death domain complex has been determined (246). These three  
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 FIGURE III.12: MyD88 S34Y does not traffic to the cell membrane upon co-
expression with Mal. (A) HEK293T cells were transfected with cerulean-tagged Mal 
either by itself or in conjunction with citrine-tagged wild type MyD88 or S34Y. Next day 
the cells were imaged using standard confocal microscopy procedures. (B) HEK293T 
cells were transiently transfected with the indicated plasmids. FRET between Mal and 
WT MyD88 or S34Y was calculated by measuring sensitized emission (SE) fluorescence 
using FRET SE wizard on the Leica SP2 confocal laser-scanning microscope. The FRET 
efficiency is shown as a color-coded scale of values between 0 to 100%.  
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FIGURE III.12: MyD88 S34Y does not traffic to the cell membrane upon  
co-expression with Mal. 
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proteins are present in a ternary complex consisting of six MyD88, four IRAK4 and four 
IRAK2 death domains. These oligomeric structures have been named “Myddosomes” by 
the authors. We hypothesized that the foci that wild type MyD88 seems to localize to 
(FIG III.9A), may be Myddosomes and the S34Y mutation ablates the ability of MyD88 
to form these oligomeric structures. According to Lin et al., the assembly of the 
myddosome is a sequential process (246). While the MyD88 death domain by itself is 
able to form oligomers at high concentration, IRAK4 and IRAK2 death domains are 
monomeric in solution. However, in the presence of MyD88, IRAK4 is oligomerized and 
forms a complex with oligomeric MyD88. This then acts as a platform for recruitment of 
IRAK2 and IRAK1. The authors believe that this hierarchical assembly is essential for 
bringing the IRAKs into a proper conformation for their phosphorylation and activation 
(246). In our study, when cerulean-tagged IRAK4 was expressed in HEK293T cells, it 
was present diffused in the cytoplasm (FIG III.13, top panel). However, when we co-
expressed citrine-tagged wild type MyD88, we observed co-localization of IRAK4 with 
MyD88 in distinct foci which we believe are Myddosomes (FIG III.13, middle panel). In 
contrast, when MyD88 S34Y was co-expressed with IRAK4, we observed both proteins 
to co-localize in the cytoplasm and have a diffuse expression pattern (FIG III.13, lower 
panel). Similar observations were made for IRAK2 and MyD88 (wild type or S34Y) co-
localization (data not shown). Thus, in agreement with Lin et al., we show that IRAK4 
and IRAK2 colocalize with MyD88 and form “Myddosomes”. The S34Y mutation 
abrogates the ability of MyD88 to form these oligomeric structures.  
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FIGURE III.13:  S34Y fails to assemble into a Myddosome: Cerulean-tagged IRAK4   
(pseudocolored red) was transfected either by itself (top panel) or in conjunction with 
citrine-tagged wild type MyD88 (middle panel) or S34Y (bottom panel) (pseudocolored 
green) into HEK293T cells. Next day the cells were imaged using sequential scanning 
and co-localization (yellow) of the two proteins was assessed. CellmaskTM (Invitrogen) 
plasma membrane stain is used to mark the cell membranes (pseudocolored blue). These 
images are representative of at least three independent experiments. 
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FIGURE III.13:  S34Y fails to assemble into a Myddosome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
124 
 
To confirm the formation of a complex between MyD88 and IRAK4, we 
examined the occurrence of FRET between IRAK4 and WT MyD88. Cerulean-tagged 
IRAK4 and citrine-tagged MyD88 were used as the donor and acceptor respectively. A 
strong FRET signal was detected between IRAK4 and WT MyD88 in the regions of 
colocalization (FIG III.14A, upper panel). Three different regions of interest (ROIs) in 
the FRET efficiency image were selected and their average was used to denote the FRET 
efficiency of the sample (FIG III.14B). FRET between WT MyD88 and IRAK4 occurred 
at a very high efficiency of 36%. Since the efficiency of FRET is inversely proportional 
to the distance between the two participating proteins, such a high FRET signal implies 
that IRAK4 and WT MyD88 interact strongly with each other and are present in a 
complex. Similar FRET experiments with the mutant MyD88 S34Y, however, yielded 
quite a low FRET signal (FIG III.14A, lower panel) with an average efficiency of 8% 
(FIG III.14B), suggesting that though both IRAK4 and S34Y are present diffused in the 
cytoplasm they are not in close proximity and do not form a functional complex, required 
for the function of MyD88. 
 The presence of a bulky amino acid at residue 34 disrupts the formation of a 
Myddosome: The published crystal structure of the Myddosome provides an opportunity 
to investigate the effect the mutation S34Y may have on the structure of MyD88.  FIG 
III.15 (A) shows the six death domains of MyD88 in the Myddosome. The residue 34 is 
colored red. The surface representation (FIG III.15 A, right panel) shows that the residue 
34 is buried within the interfaces. A change in the amino acid at residue 34 might thus 
affect the packing of these molecules. We tested this hypothesis by investigating the 
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effect of mutations at this residue in an NF-κB reporter assay (FIG III.15 B). As 
expected, WT MyD88, with serine at the 34th position was able to drive the NF-κB 
reporter. S34Y, which has a big aromatic residue at this position, was unable to acivate 
the reporter. If serine is mutated to alanine (alanine is structurally similar to serine) at this 
positon, there is no effect on the ability of MyD88 to drive the NF-κB reporter i.e., S34A 
behaves just like WT MyD88. However, upon changing the serine to phenylalanine 
(S34F), an amino acid that resembles tyrosine and is a big aromatic residue, MyD88 loses 
its ability to drive the NF-κB reporter. This suggests that the presence of a large bulky 
amino acid at residue 34 might lead to steric hindrance and may affect the formation of 
MyD88 oligomers and subsequently the Myddosome. 
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FIGURE III.14: IRAK4-S34Y FRET signal is considerably reduced as compared to 
IRAK4-MyD88 (wt): (A) HEK293T cells were transiently transfected with the indicated 
plasmids. FRET between IRAK4-cerulean (pseudocolored red) and WT MyD88-citrine 
or S34Y-citrine (pseudocolored green) was calculated by measuring sensitized emission 
(SE) fluorescence using FRET SE wizard on the Leica SP2 confocal laser-scanning 
microscope. The FRET efficiency is shown as a color-coded scale of values between 0 to 
100%. (B) FRET efficiency for both the samples (IRAK4-WT MyD88 and IRAK4-
S34Y) was obtained by calculating the average efficiency of different regions in each 
FRET image. This experiment is a representative of two independent experiments. 
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FIGURE III.14: IRAK4-S34Y FRET signal is considerably reduced as compared to 
IRAK4-MyD88 (wt) 
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FIGURE III.15: Residue 34 is buried within the interfaces in the Myddosome 
structure: (A) A ribbon representation (left panel) of the six MyD88 death domains in 
the Myddosome structure (labeled A-F). Residue 34 is colored red. Right panel: The 
same six death domains shown as surface representation. Residue 34 (red) is buried 
within the interfaces (B) HEK293T cells were transfected with the indicated MyD88 
constructs along with NF-κB-luciferase reporter. Twenty-four hours later, luciferase 
activity was measured in cell lysates. Renilla-luciferase values were used to normalize for 
transfection efficiency. The reporter only sample was used as the background and the 
depicted values are a ratio of the actual values to the background noise. Results are 
reported as a mean of triplicate determinations ± S.D. 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FIGURE III.15: Residue 34 is buried within the interfaces in the Myddosome 
structure 
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Discussion 
Toll-like receptors are critical for mounting an effective immune response against 
invading pathogens.  The signaling cascade that ensues upon ligand recognition is 
marked by finely orchestrated molecular interactions between the receptor and the TIR 
domain containing adapter proteins, as well as various downstream kinases and effector 
molecules. SNPs in the coding regions of proteins involved in such a signaling pathway 
can sometimes alter the functional properties of the protein, thus affecting the outcome of 
the signal transduction pathway.  
Human MyD88 has 6 non-synonymous SNPs in its coding region, making it one 
of the most polymorphic TLR adapter proteins. However, the effect of these SNPs on the 
function of MyD88 remains poorly understood. In our study, we have screened these 
SNPs with the hypothesis that some of them may alter the signaling potential of MyD88. 
We report that one of the polymorphisms, S34Y that lies in the death domain of MyD88, 
is a complete loss of function variant of MyD88. Of note, we did not observe a dramatic 
phenotype in MyD88 R98C, in contrast to results reported elsewhere (264). 
Cellular biological studies of signaling molecules are typically done in easily 
transfectable cells, like HEK293, which have little in common with the innate immune 
cells they are thought to represent.  Typically, studies in HEK293 cells are inherently 
compromised due to the presence of the wild-type alleles.  Using immortalized 
macrophages from MyD88 knockout animals, we have successfully reconstituted both 
fully functional macrophage cell lines and mutant macrophage lines using viral 
expression systems. These extensive studies have shown that effector cells are 
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extraordinarily destabilized by both the absence of MyD88 (as would have been 
predicted), and by S34Y.  Indeed, some of the most important effector functions, in 
addition to the activation of NF-KB and its associated downstream genes (such as TNFα), 
were clearly compromised by the expression of S34Y, including p38 activation 
downstream from TLRs 2 and 7.  When one takes into account the variety of immune 
defects that we have documented in macrophages expressing S34Y, it is no surprise that 
S34Y appears to be a rare mutation, rather than a true “polymorphism”, and is similar in 
incidence to MyD88 deficiency (240).  Indeed, we screened 267 samples from healthy 
individuals, and 105 DNA samples from children with meningococcal sepsis, and failed 
to find a single individual in either group with even a single mutant allele (data not 
shown).   Although knockout mice with MyD88 deficiency seem to survive well in our 
“clean” animal facilities, there seems to be little question that in real life, functional 
MyD88 is a necessity.   
The death domain (and the intervening region between the death and TIR 
domains) of MyD88 has earlier been implicated in the proper localization of MyD88 
(262). Nishiya et al. demonstrated that the entire non-TIR region of MyD88 is important 
to maintain the distinct and condensed pattern of MyD88 localization. In fact, there have 
been other reports that illustrate similar findings, that indeed MyD88 is present in 
aggregate structures in the cytoplasm (139, 260). Furthermore, this seems to be a 
characteristic of MyD88 that is conserved across species (265). A recent study by Liu et 
al. show that zebrafish MyD88 is also expressed as large condensed spots in the 
cytoplasm of cells and this observation is reproducible in different cell lines. Moreover, 
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there seems to be a correlation between the localization and function of MyD88. Both 
Nishiya et al. and Liu et al. find that deletions or mutations that change the expression 
pattern of MyD88 from condensed spots to diffuse cytoplasmic localization, also affect 
the function of MyD88, making it inactive in signaling. In view of all these studies, we 
compared the localization pattern of wild type MyD88 and the variant S34Y. As 
expected, wild type MyD88 was localized to large condensed spots, in the cytoplasm. 
However, S34Y had a completely different pattern of expression. It was present diffused 
in the cytoplasm and did not form any aggregates.  
The condensed spots that MyD88 seems to localize to have as yet not been 
associated with any subcellular organelle or structure. In light of the report by Lin et al. 
we propose that these aggregate structures are Myddosomes; helical oligomers of 
MyD88, IRAK4 and IRAK2 or MyD88, IRAK4 and IRAK1.  However, there is currently 
no method to study the exact stoichiometry of IRAK4/IRAK2/MyD88 aggregates inside 
the cell and hence we cannot formally demonstrate that these aggregates are 
Myddosomes. The presence of fluorescent oligomers is reminiscent of the ability to view 
other large protein assemblies devoted to innate immunity, such as the ability to view 
pyroptosome formation using fluorescent constructs of ASC that are expressed in the 
presence of an NLR and caspase 1 [the so-called “speckle” assay (60)].  Consistent with 
the findings by Lin et al. we show that MyD88 by itself is present in aggregates while 
IRAK4 is diffusely expressed in the cytoplasm. However, on co-expressing them 
together, IRAK4 co-localizes to these distinct foci along with MyD88. Most importantly, 
the mutant MyD88 S34Y is unable to form Myddosomes with IRAK4. The crystal 
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structure of the Myddosomes resolved by Lin et al. used just the death domains of the 
three proteins involved. We, on the other hand, have employed full-length proteins in all 
our studies and show for the first time the formation of Myddosomes in cells. More 
importantly, we identify a natural loss of function mutation in MyD88 that disrupts its 
ability to form Myddosome. 
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As a component of the innate immune system, TLRs are at the interface of the 
host and the environment. Any small variation in these genes can have a profound impact 
on inflammatory disease pathogenesis or the outcome of the signaling pathways 
mediating host defense. The work described in this thesis underscores the importance of 
such variation in TLR adapter proteins. With the help of two naturally occurring 
mutations in the adapter proteins Mal/TIRAP and MyD88, I illustrate two differing 
accounts of molecular changes that a polymorphism can bring about in a protein and 
hence affect its signaling capability.  
 Chapter II focuses on the SNPs in the adapter Mal, the bridging protein between 
the receptors TLR4 or TLR2 and MyD88. We characterize a rare mutation, D96N in the 
TIR domain of Mal, that is completely incapable of signaling through TLR2 and TLR4. 
We find that the presence of this mutation affects the ability of Mal to interact with 
MyD88, a necessary event for the downstream signaling to occur. A closer look at the 
molecular changes that this mutation brings about reveals the reason behind this defect. 
Although protein-protein interactions are known to be mediated by a number of forces, 
one of the major players is electrostatic forces (266). There is a significant population of 
charged and polar amino acids on the surfaces of proteins, rendering them quite polar and 
amenable to complex formation with oppositely charged proteins (267).  The surface of 
the TIR domain of Mal is largely electronegative, thus helping to bring the TIR domains 
of the receptor (TLR2/TLR4) and MyD88, both predominantly electropositive, into close 
proximity to each other (111). The lack of electrostatic complementarity prevents direct 
binding of MyD88 to TLR4 or TLR2. In the case of Mal D96N, the change from the 
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negatively charged aspartic acid (D) to the neutral asparagine (N) considerably reduces 
the net electronegative charge on the surface of the TIR domain of Mal, hence explaining 
the phenotype we see with respect to MyD88 binding. A study by George et al., report 
similar findings with respect to the loss-of-function phenotype of D96N (268). They 
however, did not see a defect in the ability of D96N to bind MyD88 in co-
immunoprecipitation assays. Nevertheless, in accordance with our study, they 
demonstrate that Mal D96N is unable to recruit MyD88 to the cell membrane using 
confocal microscopy.  
 The extremely low frequency of Mal D96N in the population is a further 
testament to the dramatic changes that this single base change can bring about to the 
function of Mal. Although, we observed a frequency of less than 1% in the population, 
George et al., genotyped a larger cohort and found heterozygous individuals at a 
frequency of 1%. However, concordant with our findings, they too were unable to find 
individuals homozygous for TIRAP D96N. It is to be expected that individuals harboring 
this mutation, even in a heterozygous form would be particularly susceptible to both 
Gram-positive and Gram-negative bacterial infections. Indeed, a recent report 
demonstrated the association of this polymorphism with tuberculosis (TB) in a Chinese 
(Han) population (269). The risk of developing TB in subjects heterozygous for the N96 
allele was found to be 13.37 fold higher than in individuals homozygous for the wild-type 
gene.  
 The sole purpose of Mal is thought to be the recruitment of MyD88 to the receptor 
complex and in this sense Mal is considered subordinate to MyD88, with no signaling 
137 
 
capabilities of its own.  However, new functions of Mal are being brought to the 
forefront. For instance, Mal has a TRAF6 binding motif that is absent in MyD88 and 
might help to bring TRAF6 to the signaling complex (140). Mutations in this motif lead 
to abrogation of TLR2 and TLR4 dependent NF-κB activation (141). Mal is also 
implicated in inhibition of TLR3 mediated IFN-β production through its interaction with 
IRF7 (270, 271). One of the most interesting findings with regard to MyD88-independent 
Mal function is the activation of PI3K dependent Akt activation by Mal upon TLR2/6 
stimulation (272). Treatment of cells with diacylated bacterial lipoproteins leads to 
interaction of Mal with p85α, the regulatory subunit of PI3K. This interaction drives 
PI3K-dependent phosphorylation of Akt, phosphatidylinositol-3,4,5-triphosphate (PIP3) 
generation and leading edge macrophage ruffling, the latter two events requiring the co-
operation of MyD88. However, Mal or MyD88 participation is not required for Akt 
activation downstream of TLR2/1. The convergence of TLR2 signaling and PI3K 
activation at the level of Mal is quite intriguing since Mal is localized to PIP2 (substrate 
of PI3K) enriched regions of the membrane via its N-terminal PIP2 binding domain 
(139). This localization of Mal is particularly important for recruiting MyD88 to the 
complex and initiating signaling.  An additional function of Mal might be to bring PI3K 
to sites rich in PIP2, its substrate, thus helping in the generation of PIP3. Localized 
concentrations of PIP2 and PIP3 play important roles in membrane ruffling and 
macrophage migration (273). PIP3 attracts a number of pleckstrin homology (PH) 
domain containing proteins like Akt as well as Rho family GTPases such as Rac and 
Cdc42. The latter two are involved in actin polymerization at the leading edge of the cell, 
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an event that precedes macrophage migration. Mal is thus not only involved in 
localization of MyD88 (and subsequent cytokine production) but also contributes to 
specific cellular responses, like production of second messengers and macrophage 
migration. Although Mal D96N is unable to recruit MyD88, it is localized to the cell 
membrane and hence we speculate that Akt activation in cells expressing D96N would 
occur normally in response to diacylated lipopeptides. However, PIP3 generation and 
macrophage polarization might be compromised since these responses require the 
involvement of MyD88. This differential response by Mal D96N could be exploited for 
therapeutic interventions and development of drugs targeting specific aspects of TLR2 
signaling. 
 Given its newfound multiplicity of roles, it is not surprising that Mal is subjected 
to multiple levels of regulation and is an important point of control for TLR2 and TLR4 
signaling (described in detail in chapter II). It is also the most polymorphic adapter 
protein with a number of studies demonstrating association of various SNPs in Mal with 
TLR2 and TLR4 mediated diseases.  Our study in chapter II not only characterizes a then 
unknown variant of Mal, D96N, but also sheds light on the region of Mal involved in 
binding MyD88, using systematic biochemical approaches. The finding that a single base 
change in Mal can abrogate its binding to MyD88, is in itself quite significant, but the 
fact that this mutation naturally occurs in the population, albeit at a low frequency, lends 
credence to our study.  
 A thorough understanding of the molecular intricacies involved in TLR signaling 
requires a detailed structural analysis of the complex formation upon signal initiation. To 
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date, attempts to co-crystallize receptor and adapter complexes have been unsuccessful. 
Recently however, Lin et al. have crystallized the death domains of MyD88, IRAK4 and 
IRAK2 in complex with each other (129). These oligomeric complexes or 
“Myddosomes” are comprised of six MyD88 death domains, followed by four IRAK4 
death domains and four IRAK2 death domains, arranged in a helical pattern. The 
structure of the Myddosome resolved by Lin et al. demonstrates that purified death 
domains of MyD88, IRAK4 and IRAK2 have a tendency to form helical oligomers in 
solution. However, whether this kind of assembly has any bearing in a physiological 
setting with full-length proteins is a question that warrants further research. Chapter III in 
this thesis enhances the understanding of this subject matter. We focus our studies on a 
death domain variant of MyD88, S34Y, that is completely defective in signaling through 
all MyD88-dependent TLR pathways. Wild-type MyD88 presents itself as 
aggregates/condensed foci in the cytoplasm. S34Y however has a dramatically different 
localization pattern. It fails to form aggregates and is diffused in the cytoplasm of the 
cell.  Moreover, while IRAK4 by itself does not form aggregates/clusters, when co-
expressed with wild-type MyD88 it colocalizes in distinct condensed aggregates. This is 
in agreement with the observations by Lin et al. and supports the idea that MyD88 likely 
acts as the platform upon which the “Myddosome” is assembled. In essence, MyD88 is 
the driving force behind the complex formation with IRAK4 and IRAK2. A study by 
George et al., reported similar findings using biochemical assays like LUMIER assay 
(274). They show that MyD88 S34Y has reduced binding to IRAK4 and thus is unable to 
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form Myddosomes, although, this defect seems to be more pronounced when just the 
death domains of the proteins are used instead of full-length proteins. 
A structural basis for the phenotype can be explained by examining the molecular 
characteristics of the amino acids involved. S34Y mutation leads to a change from serine, 
an amino acid with a small aliphatic chain, to tyrosine, a bulky aromatic amino acid, 
possibly causing steric hindrance in the protein and affecting its structural properties. 
Indeed, when serine is mutated to alanine, an amino acid with a similar side chain as 
serine (or a conservative amino acid change), the activity of S34A mutant is comparable 
to wild type MyD88 in reporter assays. On the other hand, changing serine to 
phenylalanine, an amino acid structurally similar to tyrosine, ablates the ability of 
MyD88 to signal (data not shown), suggesting that the loss-of-function effect of S34Y is 
not due to a requirement for a serine residue at that position, but rather due to the 
introduction of a bulky amino acid. The 34th position of MyD88 appears to be particularly 
vulnerable to structural changes. Whether this intolerance towards non-conservative 
changes is restricted to this residue or is extended to the surrounding region would 
require additional mutagenesis analysis. This would help in mapping the distinct areas of 
MyD88 involved in cellular localization.  
The few reports to date with the Myddosome as the subject have focused purely 
on the structural aspects of the constituents of this complex in an in vitro setting using 
purified death domains. Our studies, on the other hand, were carried out using full-length 
proteins expressed in cells. The concept of the Myddosome thus translates itself quite 
well to a cellular setting and our visualization of Myddosomes in live cells provides the 
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next step forward towards understanding the full significance of this structure. More 
importantly, we show that the S34Y mutation that ablates the ability of MyD88 to 
assemble into Myddosomes is completely inactive in MyD88-dependent signaling 
pathways. Our studies thus verify that the assembly of the proteins MyD88, IRAK4 and 
IRAK2 into Myddosomes is indeed a functional event required for MyD88 dependent 
signaling. Although not explicitly addressed in this thesis, it  is  likely  that  the  S34Y mutation  would  also  interfere with signaling downstream of receptors of the IL-1 
family. MyD88 and IRAKs are essential components of the signaling cascade 
downstream of IL-1R and IL-18R, and thus, disruption of Myddosome formation is likely 
to interfere with the function of these receptors as well.  
One of the questions that arise from the idea of the Myddosome is whether the 
assembly of this complex occurs in a ligand dependent fashion or if these signaling 
scaffolds are pre-formed in the cytosol and then recruited to the receptor upon initiation 
of signaling. While TIR-TIR interactions are considered to be unstable and transitory, 
those between death domains are relatively more stable. Conceivably, in vivo these 
complexes are held together by such DD-DD interactions and upon stimulation, this 
complex is stabilized and recruited to the receptor, which in the case of TLR4 is at the 
membrane. Conversely, these complexes may be assembled at the receptor when 
signaling is initiated; in which case MyD88 would be recruited via Mal and then 
oligomerize to form a platform for the sequential binding of IRAK4 followed by 
IRAK2/IRAK1. Our experiments support the former thought; although in the over-
expression system that we employ, the molecular excess of proteins might drive the 
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stabilization of the Myddosome, thus allowing it to be visualized even in the absence of 
stimulation. Examining the ligand dependent assembly of endogenous MyD88 and 
IRAK4 into Myddosomes would help to better address such questions. However, 
determining the stoichiometry of this complex in living cells is a challenging problem. A 
technique that has been successfully used to understand protein scaffold formation during 
signal transduction is fluorescence fluctuation spectroscopy (FFS) (275-277). It is based 
on the principle of brightness analysis of fluorescent proteins and has been utilized to 
analyze protein interactions in MAPK signaling as well nuclear receptor complexes in 
living cells (275, 278, 279).  FFS might similarly be used to comprehend the formation of 
Myddosomes. 
 The tendency to form oligomeric complexes is a characteristic of death domain 
(DD) containing proteins. The DD superfamily is one of the largest and most widely 
distributed superfamilies (166). It is evolutionarily conserved and found in many 
multicellular organisms, though the occurrence of proteins harboring this domain 
increases significantly in mammals as compared to lower organisms like C. elegans and 
Drosophila. One of the most important functions of these domains is to interact with 
other DD containing proteins to bring about the assembly of signaling complexes. DD-
DD interactions are particularly important for apoptotic and inflammatory pathways 
where oligomeric assemblies of proteins act as scaffolds for “proximity-driven 
activation” of various proteins such as kinases and ubiquitin ligases (280). In the same 
context, the formation of the Myddosome might function to bring the IRAKs into proper 
conformation to allow for phosphorylation dependent activation. Indeed, we observe that 
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the absence of Myddosome assembly in the case of S34Y precludes degradation of 
IRAK1, an event dependent upon correct phosphorylation and activation of the 
components of the Myddosome: IRAK4 and IRAK1 (FIG III.7). IRAK2 and IRAK1 have 
highly redundant roles and thus a noteworthy point is that although the structure of the 
Myddosome was resolved using the death domains of IRAK2 in complex with those of 
MyD88 and IRAK4, it can be inferred that Myddosomes could be formed with the death 
domain of IRAK1 instead of IRAK2. In either case, it is the MyD88-IRAK4 oligomeric 
complex that acts as a platform for the oligomerization of either IRAK2 or IRAK1. 
Unlike IRAK1 or IRAK2 deficient mice, the IRAK1/IRAK2 double deficient mice are 
completely resistant to LPS induced septic shock and are severely compromised in their 
ability to respond to a variety of TLR ligands (177). This supports the existence of 
Myddosomes in vivo and provides evidence that Myddosomes are not merely an artifact 
of crystallography or overexpression.  
A further deduction from the Myddosome is that higher order oligomeric 
arrangement is important for TLR signaling. The formation of such signaling platforms 
or “signalosomes” is being increasingly considered vital for regulation of various 
signaling pathways (281). For example, TLR4 and TLR2 have been reported to aggregate 
into lipid rich microdomains or lipid rafts upon stimulation (282). The binding of a ligand 
to the ectodomain of a TLR, not only induces dimerization of the receptor, but also 
affects the conformation of the TIR domains, establishing a foundation for the binding of 
the TIR domain containing adapters. In such a scenario, the recruitment of a pre-
assembled Myddosome to the receptor complex would help to further multimerize the 
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receptor complex thus enhancing the signal. Clustering of receptors or multimerization 
brought about by scaffolding platforms like the Myddosome would help to explain the 
ability of cells to adapt their affinity/sensitivity towards a particular stimulus. For 
example, even though cells express a low number of IL-1Rs, they are able to mount an 
appreciable response upon being stimulated by a relatively low concentration of IL-1 
(283, 284). This effect could be attributed to the clustering of IL-1R that the Myddosome 
can probably bring about. 
One of the major strengths of our study is the use of immortalized macrophage-
like cell lines that we generated from wild-type as well as Mal-deficient and MyD88-
deficient mice. They provide an ideal system (in the absence of transgenic mice 
expressing mutant proteins) for studying mutations in a clean genetic background in 
innate immune cells. In the absence of the wild-type Mal allele, these cells can be virally 
infected with the complementing exogenous allele or the mutant allele, allowing the 
study of the respective protein/mutant without any intervention from the endogenous 
wild-type allele. Although retroviral vectors offer some distinct advantages in terms of 
stable integration and expression in the cells, their preference for integration in 
transcriptionally active regions of the genome might result in aberrant or modulated gene 
expression. Even though we used replication deficient retroviruses in our experiments, 
random recombination between the viral and host genome can lead to the production of 
transformed viruses. Results obtained from retroviral expression of genes, should thus be 
interpreted with caution and only in the presence of appropriate controls. Experimental 
approaches employed in this thesis rely heavily on exogenous expression of the 
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respective genes, which usually results in expression of the protein at levels significantly 
higher than physiological levels. Over-expression of the protein can sometimes give rise 
to artifacts that can obscure the results. For example, in chapter III, co-
immunoprecipitation experiments with MyD88 S34Y did not reveal any defect in terms 
of binding with the known binding partners of MyD88. This could in part be due to the 
vast amount of the mutant protein being expressed in the cells, leading to non-specific 
interactions. This could also be due to the presence of endogenous MyD88 allele that acts 
as a bridge between S34Y and the interacting protein. Mere over-expression of a protein 
can also drive the respective signal transduction pathway in a ligand-independent manner 
and produce results that do not accurately reflect an activable signaling pathway. Some of 
the problems associated with over-expression studies can be circumvented by use of an 
inducible expression system. 
The events occurring at the level of the receptor complex set the stage for the 
downstream signaling. A disruption in the pathway at that point would completely 
abrogate signaling. The two mutations that form the core of this thesis affect TLR 
signaling at the level of the receptor complex, each affecting the formation of the 
signaling platform by a different mechanism. Nevertheless, the consequence of either 
mutation is a complete block in TLR signaling pathways that are mediated by that 
particular adapter protein. FIG IV.1 summarizes the effect of the two SNPs, Mal D96N 
and MyD88 S34Y on TLR signaling pathway. Mal D96N exerts its effect by preventing 
the recruitment of MyD88 to the receptor complex. On the other hand, MyD88 S34Y 
does not allow MyD88 to form oligomers, thus inhibiting the assembly of Myddosomes. 
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FIGURE IV.1: A schematic showing the effect of the mutations Mal D96N and 
MyD88 S34Y on TLR signaling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE IV.1: A schematic showing the effect of the mutations Mal D96N and 
MYD88 S34Y on TLR signaling. Mutation D96N, in the TIR domain of Mal, prevents 
the binding of Mal to MyD88. MyD88 S34Y does not allow MyD88 to form oligomers, 
thus inhibiting the assembly of Myddosomes. 
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Having studied the biochemical aspects of MyD88 S34Y, we were interested in 
the epidemiological significance of this polymorphism.  We were unable to find a single 
individual carrying MYD88 S34Y allele amongst 372 individuals we genotyped for 
MYD88. Like Mal D96N, MyD88 S34Y is an extremely rare mutant with low frequency 
in the population. This suggests that loss-of-function mutations in crucial adapter proteins 
like MyD88 and Mal encounter strong negative selection pressure. This could also 
emphasize the small sample size in our genotyping studies. Large sample sizes give better 
estimates of true population frequencies. An exhaustive attempt at genotyping TIRAP 
D96N and MYD88 S34Y might reveal a more realistic population frequency. One of the 
most extensively studied polymorphisms in adapter proteins is the serine to leucine 
change at residue 180 in Mal (224). Individuals heterozygous for this polymorphism were 
found to have increased protection against a number of TLR2 mediated diseases like 
pneumococcal disease, bacteremia, malaria and tuberculosis. Carrying this allele in a 
heterozygous setting provides an advantage to the host, possibly by ensuring an optimal 
balanced inflammatory response. A similar example of heterozygous advantage can be 
seen in the case of sickle cell trait where carriers of this trait have considerable protection 
against malaria. The aberrant protein allele has thus been maintained in the population 
despite having a deleterious effect on the function of the protein. The two mutants that we 
characterize here, however, lead to such profound changes in the signaling pathway that 
they might present a distinct disadvantage to the host in terms of defense against 
pathogens, proving them unfavorable to be maintained in the population and hence, the 
low population frequency that we observe.  
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Not many studies have associated MyD88 variants with increased susceptibility or 
protection to diseases. A report by von Bernuth et al. however, delineates the effect of 
MyD88 deficiency in nine children (240). These children exhibit high mortality rate and 
increased susceptibility to invasive streptococcal and staphylococcal disease. 
Surprisingly, they have normal resistance to many common fungi, viruses, bacteria and 
parasites. IRAK4 deficiency in children presents with a similar narrow spectrum of 
invasive diseases (285). Another report by the same group describing the clinical features 
of 45 patients with either MyD88 or IRAK4 deficiency have similar findings (286). There 
might be a number of different explanations for the unremarkable clinical history of these 
patients. It could reflect a selection bias while recruiting patients for this study and in this 
respect could be a mere artifact of selection influence. Indeed, the nine children with 
MyD88 deficiency were all selected because of their known predisposition to invasive 
pneumococcal disease. When we consider the profound effect MyD88 or IRAK4 
deficiency has in mice, the susceptibility of these patients to just a few pathogenic agents 
is quite unexpected and perhaps a more extensive study would reveal a broader spectrum 
of disease predisposition. Since these invasive infections are largely TLR2 and TLR4 
mediated, they require Mal, in addition to MyD88 for the innate immune response. Mal 
and MyD88 can lead to the activation of PI3K, one of the mechanisms implicated in 
phagocytosis of microorganisms. Signaling through Mal and MyD88 can also lead to 
changes in the levels of different phosphoinositides in the cell membrane, which can 
affect macrophage migration (273). These infections could thus be a result of 
phagocytosis defects and in the absence of the cellular effects that Mal is responsible for 
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(which would be severely compromised in a MyD88-deficient individual, since Mal 
signaling for the most part is dependent on MyD88) this infection profile is predominant 
(287). In addition, individuals with IRAK4 and MyD88 deficiencies are highly 
susceptible to bacterial infections early in life. However, upon reaching adolescence, the 
predisposition to infections decreases considerably. This could presumably be due to the 
adaptive immune mechanisms having a compensatory effect. Moreover, a majority of 
these patients are on antibiotics and without such medical intervention, these individuals 
might succumb to infections. Nevertheless, these reports allude to the importance of 
adapter proteins in host defense and imply that variants of these proteins can influence 
the outcome of life-threatening disease. Since both Mal D96N and MyD88 S34Y display 
a null phenotype with respect to signaling, we predict that the individuals carrying these 
mutations would essentially have a similar phenotype to that which has been reported for 
MyD88 or IRAK4 deficiency. 
 Conservation is generally considered a structural necessity for the function of a 
protein. The more conserved a protein, the more critical is its role. In this essence, pattern 
recognition receptors or TLRs (in the context of this thesis) are highly conserved 
receptors that act as sentinels at the interface with the environment. The functional 
domains of these signaling pathways like the TIR domain and the death domain are also 
highly conserved domains with similar function in different organisms. Conversely, the 
immune system is under constant pressure to evolve in order to successfully defend the 
host. This can be brought about in a number of different ways. Antibodies, for example, 
continue to “evolve” throughout life by means of genetic recombination. HLA molecules, 
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on the other hand, undergo extensive gene duplication to allow for subtle differences in 
antigen recognition, thus increasing the repertoire of antigens that can be recognized. To 
a similar effect, polymorphisms in the innate immune genes are a means to provide 
flexibility in the host defense mechanisms. Variation in the innate immune genes suggest 
that genes can be highly conserved across species, yet remain highly polymorphic in 
individuals within the same species. Although the two mutants we describe in this thesis 
are extremely rare variants and may not have an effect on disease susceptibility in a 
population at large, they may contribute on an “individual” level to a person’s 
immunologic competence. 
 TLR/IL-1R pathways have been implicated in a number of immune and 
inflammatory diseases like sepsis, atherosclerosis and Alzheimer’s disease (209, 223, 
288-292). In addition, they play a central role in autoimmune diseases such as systemic 
lupus erythematosus (SLE), multiple sclerosis (MS) and inflammatory bowel disease 
(IBD) (293-297) (298). Therapeutic targeting of TLR/IL-1R signaling is thus increasingly 
gaining attention as a potentially viable approach for many diseases of the immune 
system. Protein-protein interactions are a hallmark of every signaling pathway and 
provide an important tool for modulating the activity of TLR pathways. Intriguingly, 
several microbes utilize similar strategies for evading the innate immune responses. Mal 
and MyD88 appear to be particularly amenable to such interventions by the microbes. 
Viral inhibitory peptide of TLR4 (or VIPER) is a TIR domain containing-protein from 
Vaccinia virus (299). It binds to Mal and TRAM; masks critical binding sites on the 
surface of these two proteins and specifically inhibits TLR4. A number of genes encoding 
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TIR domain containing–proteins (Tcps) have been identified in different bacteria such as 
E.coli, Salmonella enterica and Brucella melitensis (300, 301). These proteins act as 
mimetics of the signaling domains, thus blocking the signaling pathway (302, 303). 
Taking cues from the pathogens, the development of various decoy peptides has been 
undertaken to target TLR function. These are short peptides that are expected to mimic 
the interaction surface of a particular protein and prevent the interactions between the 
prototype binding partners. Our study unveils two novel targets for the development of 
such TLR inhibitors. The BB loop region (connects the second β-sheet and the second α-
helix of the TIR domain) of TIR domain has received the most attention as therapeutic 
targets. The work presented in this thesis highlights other regions in the TIR domain of 
Mal (and perhaps other adapters) that can serve as valuable therapeutic targets. We also 
delineate a single residue in the death domain of MyD88 that is absolutely essential for 
its function and thus illustrates a unique approach to TLR targeting. 
 By means of the studies presented in this thesis, I attempt to highlight the 
importance of amino acid changes in TLR adapter proteins. Such changes can have an 
effect on predisposition and outcome of various diseases. They also reveal invaluable 
information about the structure and function of the protein involved and provide novel 
drug targets. Systematic studies investigating the effect of natural variation in other 
adapter proteins, would not only help in understanding the molecular biology of these 
proteins, but also bring to the forefront distinct genetic variants that affect disease 
prognosis. 
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Future Prospects 
 Despite tremendous growth in the field of TLR signaling, the molecular workings 
and intricacies of adapter proteins with respect to their differential use by various TLRs, 
remains obscure. In vivo studies in transgenic mice expressing loss-of-function variants 
would shed light on some of these effects. These mice would not only provide clues 
about the spectrum of infections and outcomes that we could expect in individuals 
harboring these variants, but would also be an ideal experimental system to answer 
questions about various biochemical aspects of adapter proteins. For example, cells from 
these mice could be used for phagocytosis assays, interaction studies, lymphocyte 
proliferation assays. In the case of MyD88, an interesting facet is the apparent reliance of 
MyD88-dependent signaling on the formation of the Myddosomes. Mice expressing the 
S34Y mutant of MyD88 may help to further clarify this aspect. 
Finally, some longstanding yet unanswered questions remain that are worth 
mentioning. First, in the absence of Mal and TRAM (for example, in the case of TLR5, 
TLR7 and TLR3 respectively), how are MyD88 and TRIF recruited to the receptors? Do 
additional adapters/factors remain undiscovered and would the discovery of such 
proteins, change the existing paradigms of TLR signaling? Second, Why can MyD88 
signal through both surface as well as endosomal TLRs, whereas TRIF can only signal 
from the endosomes? Lastly, is the ability to signal from both the cell surface as well as 
the endosomes unique to TLR4, or do all the TLRs possess the capability to shuttle 
between the cell membrane and the endosomal-endoplasmic reticulum network and a 
plethora of signaling networks are just waiting to be revealed? 
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